WO1985000806A1 - Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues - Google Patents

Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues Download PDF

Info

Publication number
WO1985000806A1
WO1985000806A1 PCT/US1984/000280 US8400280W WO8500806A1 WO 1985000806 A1 WO1985000806 A1 WO 1985000806A1 US 8400280 W US8400280 W US 8400280W WO 8500806 A1 WO8500806 A1 WO 8500806A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
tumor promotion
animal
combined
acceptable carrier
Prior art date
Application number
PCT/US1984/000280
Other languages
French (fr)
Inventor
Marcia Ilton Dawson
Rebecca Leung-Shun Chan
Peter D. Hobbs
Original Assignee
Sri International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sri International filed Critical Sri International
Publication of WO1985000806A1 publication Critical patent/WO1985000806A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/546—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/792—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic containing rings other than six-membered aromatic rings

Definitions

  • the invention is in the fields of retinoid chemistry and chemotherapy. More particularly the invention relates to certain benzonorbornenyl, dihydrobenzopyranyl and dihydrobenzothiopyranyl retinoic acid analogues.
  • Retinoic acid and some of its analogues have been investigated as "chemopreventive" agents, that is, agents that interfere with tumor promotion in epithelial cells.
  • the first Dawson, M.I., et al, article describes the synthesis of ethyl (E)-3,7-dimethyl-9-(exobicyclo[2.2.1]hept-2-en-2-yl)-2,4,6,8-nonatetraenoate.
  • This compound is highly labile but exhibited activity in the ornithine decarboxylase (ODC) assay, which assay is described by Verma, A.K. and Boutwell, R.K., Cancer Res (1977) 37:2196-2201.
  • ODC ornithine decarboxylase
  • aromatic retinoic acid analogues also exhibited biological activity in the ornithine decarboxylase (ODC) assay.
  • ODC ornithine decarboxylase
  • Other reported aromatic retinoic acid analogues with biological activity are 4-[(E)-2-(1,2,3,4tetrahydro-1,1,4,4-tetramethyl-6-napthyl)-1-propen-1yl]benzoic acid and ethyl 4-[(E)-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-1-propen-1yl]benzoate.
  • a principal object of this invention is to provide retinoic acid analogues which are biologically active and which may exhibit lesser toxicity than other retinoic acid analogues.
  • retinoic acid analogues of the invention are compounds of the formula:
  • A is the substituent system of a fused ring selected from:
  • R 1 , R 2 , R 3 and R 4 are hydrogen or methyl, X is hydrogen or fluorine and Q is:
  • X 1 is hydrogen, hydroxy, methoxy or fluorine
  • R is hydroxy, alkoxy with 0 or 1 hydroxy substituent, aroxy or NR 5 R 6 , where R 5 is hydrogen, alkyl with 0 or 1 hydroxy substituent or aryl and R 6 is alkyl with 0 or 1 hydroxy substituent or aryl, with the provisos that X is fluorine only when R 2 is methyl, when R 3 or R 4 is methyl, the other R 3 or R 4 is also methyl, and when Q is (i) Q may be in either the cis or trans position.
  • retinoids When used as pharmaceuticals, eg, as a chemopreventive agent or for treating skin disorders such as proliferative skin diseases or acne, one or more of these retinoids is combined with a suitable pharmaceutically acceptable carrier and an effective dose thereof is administered to the patient.
  • a suitable pharmaceutically acceptable carrier When used as pharmaceuticals, eg, as a chemopreventive agent or for treating skin disorders such as proliferative skin diseases or acne, one or more of these retinoids is combined with a suitable pharmaceutically acceptable carrier and an effective dose thereof is administered to the patient.
  • the alkoxy groups represented by R will usually contain 1 to about 10 carbon atoms and have 0 or 1 hydroxy substituent. They will preferably contain 1 to 4 carbon atoms, and have 0 or 1 hydroxy substituent..
  • the alkoxy groups represented by R may be straight chain or branched chain. Examples of such alkoxy groups are methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, n-hexoxy, 2-methylpentoxy, n-heptoxy, 2-hydroxyethoxy, 3-methylhexoxy, n-octoxy, and n-decoxy.
  • the aroxy groups represented by R will usually be mononuclear and contain 6 to 15 carbon atoms, more usually 6 to 10 carbon atoms and have 0 or 1 hydroxy or C 1 -C 4 alkoxy substituent.
  • Preferred aroxy groups are phenoxy and hydroxy- or C 1 -C 4 alkoxy-monosubstituted phenoxy.
  • Examples of aroxy groups are phenoxy, o- , m-, or p-hydroxyphenoxy, o-, m-, or p-methoxyphenoxy, toloxy, cumoxy, xyloxy, and naphth ⁇ xy.
  • the alkyl groups represented by R 1 and R 2 may be straight chain or branched chain.
  • alkyl groups are methyl, ethyl, propyl, isopropyl, n -butyl, s-butyl, n -amyl, n-hexyl, 2-methylamyl, n-heptyl, 3-methylhexyl, n-octyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydfoxyhexyl, and the like.
  • the corresponding aryl groups represented by R 1 and R 2 may be substituted or unsubstituted mononuclear or polynuclear moieties.
  • the substituents will usually be lower (ie, 1 to 4 carbon atoms) alkyl, monohydroxyalkyl, lower alkoxy, monohydroxyalkoxy or hydroxy. When substituted, the group will usually be mono-substituted. Examples of such groups are phenyl, o- , m-, or p-hydroxyphenyl, o-, m-, or p-methoxyphenyl, ethylbenzyl, cumyl, and the like. These aryl groups will usually contain 6 to about 15 carbon atoms, more usually 6 to 10 carbon atoms. Phenyl, 4hydroxyphenyl, and 4-methoxyphenyl are preferred aryl groups.
  • esters and esters of the other aromatics may be made by starting with the desired phosphonate of the appropriate aromatic carboxyl ester.
  • the carboxamides may be made from the acids by conversion to acid chlorides or activated esters followed by reaction with an appropriate amine.
  • the dihydrobenzothiopyranyl retinoids of formula 1 may be made by the following schemes:
  • dihydrobenzopyrans are made analogously from the oxygen analog of 2,3-dihydro-4,4-dimethyl-1benzothiopyran (compound 5 in the above scheme):
  • esters and esters of other aromatics of the benzopyran and benzothiopyran compounds may be made by varying the phosphonate reactant.
  • Cyclopentadiene (bp 39-40oC) was prepared by heating the dimer and distilling twice through a 10-cm Vigreaux column packed with glass helices. It was stored at -78oC before use.
  • 1,4-Methano-1,2,3,4-tetrahydronaphthalene To 16.0 g (0.113 mol) of the purified 1,4-methano-1,4-dihydronaphthalene in 150 mL of absolute EtOH was added 1.0 g of 5% Pd/C. This mixture was hydrogenated at room temperature and atmospheric pressure. After about 20 h, TLC indicated that no starting material remained.
  • 6-Acetyl-1,4-methano-1,2,3,4-tetrahydronaphthalene A mixture of 6.9 g (47.9 mmol) of 1,4-methano-1,2,3,4tetrahydronaphthalene and 4.14 g (52.7 mmol) of AcCl was added dropwise over a period of 20 min to a stirred suspension of 7.34 g (55 mmol) of AlCl 3 in 50 mL of ClCH 2 CH 2 Cl, which was cooled in a water bath at 20oC . When the addition was complete, the mixture was stirred at room temperature for 1 h. The reaction was quenched with 100 mL of ice-water and extracted with Et 2 O (2 x 150 mL).
  • This oil was partially purified on 150 g of silica gel (7% Et 2 O/hexane) to give 3.0 g of the unrea ⁇ ted starting material, 6-acetyl-1,4-methano-1,2,3,4-tetrahydronaphthalene, and 7.0 g (70% yield from the amount of ketone consumed) of an approximately 2:1 mixture of Z and E isomers, (Z)-1-(4-carbethoxyphenyl)-2-(1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene and (E)-1-(4-carbethoxyphenyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1- ⁇ ropene, respectively.
  • Phenyl 3,3-Dimethylthiolacrylate To a degassed (argon) suspension of -NaH, which was obtained from 3.2 g (80 mmol) of 60% NaH/mineral oil dispersion, which had been washed with hexane (3 x 15 mL) under argon, in 30 mL of THF, was added over a period of 5 min with stirring and cooling in ice a solution of 8.8 g (80 mmol) of thiophenol in 80 mL of THF.
  • the suspension was stirred for a further 15 min and then treated with a solution of 10.1 g (85 mmol) of 3,3dimethylacryloyl chloride in 40 mL of THF over a period of 10 min and then allowed to warm to room temperature over a 2-h period.
  • the suspension was poured into 200 mL of water containing 2 mL of HOAc and stirred for 15 min and then extracted with 200 mL of Et 2 O.
  • the extract was washed with dilute brine (3 x 100 mL), dried (Na 2 SO 4 ), and concentrated to give a yellow oil.
  • Method B To a solution of 22.9 g (88 mmol) of SnCl 4 in 200 mL of CH 2 Cl 1 , cooled in ice, was added a solution of 7.83 g (44 mmol) of 3-methyl-2-buten-1-yl phenyl sulfide in 40 mL of CH 2 Cl 2 . The solution was stirred at 0-5oC for 20 min and then at room temperature for 20 h. The red solution was poured onto 500 g of ice/brine,' and the organic extract was washed successively with 250-mL volumes of brine, aqueous
  • the suspension was stirred for 40 min before a solution of 9.3 g (62.4 mmol) of 3,3-dimethylallyl bromide in 25 mL of THF was added over a 10-min period, while the reaction mixture was maintained at ice-bath temperature. The reaction mixture was stirred for a further 45 min and then allowed to warm to room temperature over a 1.25-h period.
  • the white suspension was poured into 300 mL of water. The organic phase was washed with 150 mL of 1 N NaOH solution and twice with 150 mL of dilute brine and dried (Na 2 SO 4 , overnight).
  • 6-Acetyl-2,3-dihydro-4,4-dimethyl-1-benzothiopyran A solution of 1.3 g (16.6 mmol) of acetyl chloride and 2.85 g (16.0 mmol) of 2,3-dihydro-4, 4-dimethyl-1benzothiopyran in 50 mL of CS 2 was added dropwise over a 15-min period to 3.2 g (24.0 mmol) of AlCl 3 with stirring and cooling in ice. The additon funnel was rinsed with 10 mL of CS 2 . The reaction mixture was stirred at room temperature for 2.25 h, before the resultant orange suspension was treated with 50 mL of ice/brine.
  • the mixture was again degassed (twice) and then heated at reflux in a 100-110oC oil bath for 40 min.
  • the ester dissolved within 15 min to give a pale-yellow solution.
  • the reaction mixture was cooled to room temperature, quenched with a solution of 2 mL of HOAc in 10 mL of water, and then diluted with 10 mL of brine. Because the white, solid carboxylic acid failed to dissolve in Et 2 O, it was extracted out with EtOAc (100 mL, then 50 mL).
  • the very pale-yellow extract was washed with dilute brine (2 x 25 mL) and water (25 mL), dried (Na 2 SO 4 ), and concentrated.
  • Method B as shown on page 17 employed an intramolecular Friedel-Crafts alkylation (Milstien, S., et al, supra) of phenyl 3,3-dimethylacrylate to give the lactone, 2,3-dihydro-4,4-dimethyl-2-oxo-1-benzopyran, which was reduced to the diol (compound 18 on page 17, Borchardt, R.T., et al, supra), and the primary alcohol group of which was selectively esterified as the mesylate. Intramolecular displacement of the mesylate by phenoxide ion gave 2,3-dihydro-4,4dimethyl-1-benzopyran in 71% overall yield from phenol.
  • the olefin (E)-1-(4-carbethoxy ⁇ henyl)-2-(4,4-dimethyl2,3-dihydro-1-benzopyran-6-yl)-1-propene was prepared from 6-acetyl-2,3-dihydro-4,4-dimethyl-1-benzopyran by Horner-Emmons reaction using diethyl 4-carbethoxybenzyl phosphonate in the presence of 15Crown-5 at room temperature. Surprisingly, the reaction was not completely stereoselective. (6) The major, E-isomer was easily isolated in 57% yield by crystallization from hexane.
  • Method B To a degassed (3 times, argon) suspension of NaH, obtained from 2.15 g (54 mmol NaH) of 60% NaH/mineral oil, which had been washed with hexane (3 x 10 mL), in 20 mL of THF was added over a 5-min period with stirring and cooling in ice a solution of 5.0 g (53 mmol) of phenol in 55 mL of THF. The suspension was stirred for a further 10 min, treated with a solution of 7.0 g (59 mmol) of 3,3-dimethylacryloyl chloride in 27 mL of THF over a 5-min period, and then allowed to warm to room temperature over a 3h period.
  • the suspension was poured into 150 mL of water containing 1 mL of HOAc. The mixture was stirred for 15 min and extracted with 150 mL of Et 2 O. The extract was washed with dilute brine (2 x 100 mL) and water (100 mL), dried (Na 2 SO 4 ), and concentrated to give a pale yellow liquid.
  • This purified ester (9.0 g, 51.1 mmol) in 50 mL of CH 2 Cl 2 was added to a stirred, ice-cooled suspension of 12.0 g (90 mmol) of AlCl 3 in 200 mL of CH 2 Cl 2 .
  • This suspension was stirred at room temperature for 63 h to give a dark brown solution, which was poured onto 500 mL of ice/brine and then extracted with 150 mL of CH 2 Cl 2 .
  • the brown extract which contained some suspended solid and aqueous emulsion, was filtered to separate out a dark-red organic phase.
  • the suspension was stirred at room temperature for 16 h to give a red gum and a red solution.
  • the reaction mixture was treated with 200 mL of brine containing 1 mL of HOAc and extracted with Et 2 O (2 x 150 mL). The extract was washed with water (150 mL), dried (Na 2 SO 4 ), and concentrated. The yellow oil was eluted through a 4.5 x 35-cm silica gel column with 7%
  • the cold white suspen- sion was diluted with 5 mL of 50% HOAc and 50 mL of brine.
  • the product was extracted into 500 mL of 50% Et 2 O/THF.
  • the extract was washed with dilute brine (2 x 100 mL), dried (MgSO 4 ), and concentrated.
  • the white solid was dissolved in 250 mL of 50% EtOAc/C 6 H 6 at reflux.
  • 1,2,3,4-Tetrahydro-1,4-methano-6-naphthoic Acid To a solution of 60 g (1.5 mol) of NaOH in 300 mL of H 2 O cooled to -5°C was added 25.6 mL (0.5 mol) of Br 2 over a period of 5 min. The resulting solution of NaOBr was kept below 0°C, while a solution of 18.6 g (0.1 mol) of 1,2,3,4-tetrahydro-6-acetyl-1,4-methanonaphthalene in 10 mL of dioxane was added. The temperature of the reaction mixture was gradually raised to 60-65°C with a hot-water bath and was maintained there for 0.5 h.
  • reaction mixture was then cooled to room temperature, before a solution of 50 g (0.48 mol) of NaHSO 3 in 200 mL of H 2 O was added.
  • the yellow reaction mixture turned colorless.
  • the mixture was acidified with about 120 mL of concentrated HCl; and the white, precipitated acid was extracted into 800 mL of Et 2 O.
  • the ethereal solution was dried (Na 2 SO 4 ) and concentrated.
  • the naphthoic acid prepared as described above (9.4 g, 0.05 mol) was added slowly to a stirred suspension of 1.0 g (26.4 mmol) of LiAlH 4 in 100 mL of THF. Another 0.6-g (15.8 mmol) portion of LiAlH 4 was then added. This mixture was stirred at room temperature for 2 h, when TLC (25% EtOAc/hexane) indicated that no starting material remained. To the reaction mixture was slowly added 1.6 mL of H 2 O, 4.8 mL of 15% aqueous NaOH, and 1.6 mL of H 2 O. The mixture was filtered through Celite (100-mL Et 2 O wash).
  • the retinoids of formula (1) may be used topically or systemically as chemopreventive agents and in the treatment, amelioration, or prevention of the skin, rheumatic and other disorders for which retinoic acid and other retinoids are useful.
  • they may be used for therapy in animals, including humans, of premalignant epithelial cell lesions, as a prophylaxis against tumor promotion in epithelial cells and treatment for dermatoses such as icthyoses, follicular disorders, benign epithelial disorders, and other proliferative skin diseases (nonmalignant conditions of the skin that are characterized by epidermal cell proliferation or incomplete cell differentiation) such as acne, psoriasis, eczema, atopic dermatitis, nonspecific dermatitis and the like.
  • a pharmaceutically acceptable carrier is a material that is nontoxic and generally inert and does not affect the functionality of the active ingredients adversely. Such materials are well known and include those materials sometimesreferred to as diluents or vehicles in the pharmaceutical formulation art.
  • the carrier may be organic or inorganic in nature.
  • Examples of pharmaceutically acceptable carriers that may be used to formulate the retinoids are water, gelatin, lactose, starch, mineral oil, cocoa butter, dextrose, sucrose, sorbitol, mannitol, gum acacia, alginates, cellulose, talc, magnesium stearate, polyoxyethylene sorbitan monolaurate, and other commonly used pharmaceutical carriers.
  • the formulation may contain minor amounts of additives such as flavoring agents, coloring agents, thickening or gelling agents, emulsifiers, wetting agents, buffers, stabilizers, and preservatives such as antioxidants.
  • the retinoids are conveniently provided in the form of ointments, tinctures, creams, solutions, lotions, sprays, suspensions, and the like.
  • the amount of retinoid in such topical formulations will normally be in the range of about 0.01 to about 1% by weight.
  • enteral (oral or rectal) administration the retinoids will typically be formulated as tablets, capsules, dragees, syrups, solutions, or suppositories.
  • parenteral administration the retinoids will be formulated as injectable solutions or suspensions.
  • the dosages and dosage regimen in which the retinoids are administered will vary according to the dosage form, mode of administration, the condition being treated and particulars of the patient being treated. They will, of course, be administered in chemopreventive (tumor promotion inhibiting) amounts or therapeutically effective amounts. For adult humans such chemopreventive amounts will usually be about 0.01 mg to 10.0 mg daily given in one or more doses. Oral doses will generally be more than topical doses and doses for treating skin disorders will typically be less than doses administered for cancer chemoprevention. The dose for treating skin disorders will be on the order of, but normally less than, the dose of retinoic acid prescribed for the disorder. The usefulness of the invention compounds was demonstrated by testing the compounds of the
  • ODC ornithine decarboxylase
  • the ODC assay is carried out as follows. Female Charles River CD-I mice from Charles River
  • TPA 12-O-tetradecanoylphorbol-13-acetate
  • the epidermis is obtained from the sacrificed animals. To obtain sufficient material, the dorsal skins from 2 to 3 mice in each treatment group are pooled. The depilatory agent Nudit® (Helena Rubinstein, New York) is applied to the shaved area of the skin; after 5 minutes, it is washed off thoroughly with cold tap water. Then the skin is excised and plunged immediately into ice-cold water; it is then placed in a 55°C water bath for 30 seconds and reimmersed in ice-cold water for at least another 30 seconds. The skin is placed epidermis side up on a cold plate, and the epidermis is scraped off with a razor blade.
  • Nudit® Helena Rubinstein, New York
  • the pooled epidermal sheets are homogenized (Polytron PT-10 homogenizer) at 0° to 4°C for 1520 seconds in 50 mM sodium phosphate and 0.1 mM ethylenediaminetetraacetic acid (EDTA), at a volume of 1 mL/skin.
  • Polytron PT-10 homogenizer Polytron PT-10 homogenizer
  • EDTA ethylenediaminetetraacetic acid
  • the supernatant fraction remaining after centrifugation of the homogenate at 10,000 x g for 30 seconds at 0°C is used for the enzyme assay. Enzyme activity is determined using the microassay for ODC as described by Verma and Boutwell to measure the release of 14 CO 2 from DL-[1- 14 C]-ornithine (58 mCi/mmol) after incubation with the 10,000 x g supernatant. The incubations are carried out by decanting, with a Pasteur pipette, 100 ⁇ L of the supernatant containing 100 to 120 ⁇ g of protein into two or three 15-mL Corex tubes in a shaking water bath at 37°C.
  • the assay mixture in the tubes consists of 50 ⁇ L of 100 ⁇ M sodium phosphate buffer (pH 7.2), 10 ⁇ L of 4 ⁇ M pyridoxal phosphate, 40 ⁇ L of 25 mM dithiothreitol, and 1 ⁇ L of 0.1 M EDTA.
  • the center wells in the tubes are filled with 200 ⁇ L of a 2:1 solution (v/v) of ethanolamine:2methoxyethanol.
  • the reaction is started by adding 50 ⁇ L of substrate (0.5 ⁇ Ci of DL-[1- 14 C]-ornithine in 2 mM cold ornithine) at 1-minute intervals by injection to each of the stoppered tubes. Incubations are routinely carried out at 37oC for 30 to 60 minutes.
  • the reaction is stopped by addition of 0.5 ml of 2 M citric acid, and incubation is continued for an additional hour without heating to ensure complete absorption of 14 CO 2 .
  • Radioactivity is measured using a toluenebased scintillant (4 g of PPO and 50 mg of POPOP/L of toluene) in a Beckman LS-250 liquid scintillation counter.
  • Enzyme activity is determined in triplicate and expressed as nanomoles of CO 2 released in 30 minutes per milligram of protein. Enzyme activity is linear for the protein concentration used.
  • the protein concentrations of the epidermal extracts are determined by the Lowry procedure, using bovine serum albumin as the standard.
  • the tracheal organ culture assay is carried out as follows. Tracheas are taken from hamsters that are in very early stages of vitamin A deficiency and placed in organ culture. At the time of culture, the animals are still gaining weight; the tracheal epithelium is generally low columnar or cuboidal, with only occasional patches of squamous metaplasia.
  • Each trachea is opened from the larynx to the carina along the membranous dorsal wall and cultured in a serumfree medium (CMRL-1066; with crystalline bovine insulin, 0.1 ⁇ g/ml; hydrocortisone hemisuccinate, 0.1 ⁇ g/ml; glutamine, 2 mM; penicillin, 100 units/ml; and streptomycin, 100 ⁇ g/ml, added).
  • Cultures are gassed with 50% oxygen, 45% nitrogen, and 5% CO 2 .
  • the culture dishes are rocked at 35.5-36.0 degrees to allow the tracheas contact with both gas and medium. All tracheas are grown in medium containing no retinoid for the first 3 days.
  • tracheas are harvested; almost all of these tracheas have significant squamous metaplasia, and approximately 60% have keratinized lesions.
  • the remaining tracheas are then divided into different groups which are treated with either: 1) retinoid dissolved in dimethylsulfoxide (final concentration of DMSO in culture medium is never greater than 0.1%) or 2) an equivalent amount of DMSO alone.
  • Culture medium is changed three times a week, and all of the remaining tracheas are harvested at the end of 10 days in culture. Tracheas are fixed in 10% buffered formalin and embedded in paraffin.

Abstract

Compounds of the formulas (I), (II) and (III), where R1, R2, R3 and R4 are hydrogen or methyl, X is hydrogen or fluorine and Q is formula (IV), (V), (VI), (VII), (VIII), or (IX), and X1 is hydrogen, hydroxy, methoxy or fluorine, R is hydroxy, alkoxy with 0 or 1 hydroxy substituent, aroxy or NR5R6, where R5 is hydrogen, alkyl with 0 or 1 hydroxy substituent or aryl, and R6 is alkyl with 0 or 1 hydroxy substituent or aryl, with the provisos that X is fluorine only when R2 is methyl, when R3 or R4 is methyl the other R3 or R4 is also methyl and when Q is said thienyl group Q may be in either the cis or trans position. These compounds are useful as chemopreventive agents for inhibiting tumor promotion in epithelial cells and for treating nonmalignant skin disorders.

Description

BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES
Reference to Government Grant or Contract
The invention described herein was made in the course of work under grant from the National Institutes of Health.
Description
Technical Field
The invention is in the fields of retinoid chemistry and chemotherapy. More particularly the invention relates to certain benzonorbornenyl, dihydrobenzopyranyl and dihydrobenzothiopyranyl retinoic acid analogues.
Background Art The progressive loss of the regulation of cellular differentiation by epithelial cells can result in cancer. Retinoic acid and some of its analogues (retinoids) have been investigated as "chemopreventive" agents, that is, agents that interfere with tumor promotion in epithelial cells.
Boutwell, R.K., et al. Advances in Enzyme Regulation V.17, Weber, G., (Ed.), Pergamon Press (1979); Verma, A.K., et al. Cancer Res (1979) 39:419-427; Dawson, M.I., et al, J Med Chem (1980) 23:51013-1022, J Med Chem (1981) 24:583-592, and J Med Chem (1981) 24:12141223.
The first Dawson, M.I., et al, article describes the synthesis of ethyl (E)-3,7-dimethyl-9-(exobicyclo[2.2.1]hept-2-en-2-yl)-2,4,6,8-nonatetraenoate. This compound is highly labile but exhibited activity in the ornithine decarboxylase (ODC) assay, which assay is described by Verma, A.K. and Boutwell, R.K., Cancer Res (1977) 37:2196-2201. In the latter Dawson article the synthesis of an analogue of the above described norbornenyl retinoid is reported. This compound, ethyl (E)-3, 7-dimethyl-9-(exo-2-bicyclo[2.2.1]heptyl)-2, 4,6, 8-nonatetraenoate, also exhibited activity in the ODC assay.
The second Dawson article, J Med Chem (1981) 24:583-592, describes the preparation of (1E, 3E)- and (1Z , 3E)-1-(4-carboxyphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadiene, the methyl and ethyl enters thereof, (E)-1-(2-carboxyphenyl)-4methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1 ,3,5hexatriene, the methyl ester thereof, (E)-1-[2-(tetrahydropyranyloxy)phenyl]-4-methyl-6-(2,6,6-trimethyl-1cyclohexen-1-yl)-1,3,5-hexatriene and the (1E, 3Z, 5E) isomer thereof, and (E)-1-(2-hydroxyphenyl)-4-methyl6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3,5-hexatriene and its (1E, 3Z, 5E) isomer. Some of these aromatic retinoic acid analogues also exhibited biological activity in the ornithine decarboxylase (ODC) assay. Other reported aromatic retinoic acid analogues with biological activity are 4-[(E)-2-(1,2,3,4tetrahydro-1,1,4,4-tetramethyl-6-napthyl)-1-propen-1yl]benzoic acid and ethyl 4-[(E)-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-1-propen-1yl]benzoate. These compounds exhibit very marked therapeutic effect against carcinogen-induced skin papillomas, Loeliger, P., et al, Eur J Med Chem - Chemica Therapeutica (1980) 15:9-15 and West German Patent No. 2,854,354.
A principal object of this invention is to provide retinoic acid analogues which are biologically active and which may exhibit lesser toxicity than other retinoic acid analogues.
Disclosure of the Invention
The retinoic acid analogues of the invention are compounds of the formula:
Figure imgf000005_0002
where A is the substituent system of a fused ring selected from:
Figure imgf000005_0001
and R1, R2, R3 and R4 are hydrogen or methyl, X is hydrogen or fluorine and Q is:
Figure imgf000006_0001
where X1 is hydrogen, hydroxy, methoxy or fluorine, R is hydroxy, alkoxy with 0 or 1 hydroxy substituent, aroxy or NR5R6, where R5 is hydrogen, alkyl with 0 or 1 hydroxy substituent or aryl and R6 is alkyl with 0 or 1 hydroxy substituent or aryl, with the provisos that X is fluorine only when R2 is methyl, when R3 or R4 is methyl, the other R3 or R4 is also methyl, and when Q is (i) Q may be in either the cis or trans position.
When used as pharmaceuticals, eg, as a chemopreventive agent or for treating skin disorders such as proliferative skin diseases or acne, one or more of these retinoids is combined with a suitable pharmaceutically acceptable carrier and an effective dose thereof is administered to the patient. Modes for Carrying Out the Invention
The alkoxy groups represented by R will usually contain 1 to about 10 carbon atoms and have 0 or 1 hydroxy substituent. They will preferably contain 1 to 4 carbon atoms, and have 0 or 1 hydroxy substituent.. The alkoxy groups represented by R may be straight chain or branched chain. Examples of such alkoxy groups are methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, n-hexoxy, 2-methylpentoxy, n-heptoxy, 2-hydroxyethoxy, 3-methylhexoxy, n-octoxy, and n-decoxy. The aroxy groups represented by R will usually be mononuclear and contain 6 to 15 carbon atoms, more usually 6 to 10 carbon atoms and have 0 or 1 hydroxy or C1-C4 alkoxy substituent. Preferred aroxy groups are phenoxy and hydroxy- or C1-C4 alkoxy-monosubstituted phenoxy. Examples of aroxy groups are phenoxy, o- , m-, or p-hydroxyphenoxy, o-, m-, or p-methoxyphenoxy, toloxy, cumoxy, xyloxy, and naphthσxy. The alkyl groups represented by R1 and R2 may be straight chain or branched chain. They will typically each contain 1 to 8 carbon atoms with 0 or 1 hydroxy substituent, preferably 1 to 4 carbon atoms, and have 0 or 1 hydroxy substituent. Examples of such alkyl groups are methyl, ethyl, propyl, isopropyl, n -butyl, s-butyl, n -amyl, n-hexyl, 2-methylamyl, n-heptyl, 3-methylhexyl, n-octyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydfoxyhexyl, and the like. The corresponding aryl groups represented by R1 and R2 may be substituted or unsubstituted mononuclear or polynuclear moieties. The substituents will usually be lower (ie, 1 to 4 carbon atoms) alkyl, monohydroxyalkyl, lower alkoxy, monohydroxyalkoxy or hydroxy. When substituted, the group will usually be mono-substituted. Examples of such groups are phenyl, o- , m-, or p-hydroxyphenyl, o-, m-, or p-methoxyphenyl, ethylbenzyl, cumyl, and the like. These aryl groups will usually contain 6 to about 15 carbon atoms, more usually 6 to 10 carbon atoms. Phenyl, 4hydroxyphenyl, and 4-methoxyphenyl are preferred aryl groups.
Examples of acids (R = OH) are: (E )-1-(4-carboxypheny1)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1-propene
(E)-1-(4-carboxy-2-fluorophenyl)-2-(1,4-methano1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E )-1-(4-carboxy-2-hydroxyphenyl)-2-(1,4-methano1,2,3,4-tetrahydro-6-naphthyl)-1-proρene (E)-1-(4-carboxy-2-methoxyphenyl)-2-(1,4-methano1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E) -1-(2-carboxy-5-pyridyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1-propene (E )-1-(2-carboxy-4-imidazolyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1-propene
(E )-1-(2-carboxy-5-pyrazinyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1-propene (E )-1-(2-carboxy-5-pyrimidinyl)-2-(1,4-methano1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(2-carboxy-5-thienyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1-propene
(Z)-1-(2-carboxy-5-thienyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxyphenyl)-2-(1,4-methano-7-methyl1,2,3,4-tetrahydro-6-naphthyl)-1-propene
(E)-1-(4-carboxy-2-fluorophenyl)-2-(1,4-methano-7methyl-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxy-2-hydroxyphenyl)-2-(1,4-methano-7methyl-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxy-2-methoxyphenyl)-2-(1,4-methano-7methyl-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(2-carboxy-5-pyridyl)-2-(1,4-methano-7-methyl1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E )-1-(2-carboxy-4-imidazolyl)-2-(1,4-methano-7methyl-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(2-carboxy-5-pyrazinyl)-2-(1,4-methano-7-methyl1,2,3,4-tetrahydro-6-naρhthyl)-1-propene (E )-1-(2-carboxy-5-pyrimidinyl)-2-(1,4-methano-7methyl-1,2,3,4-tetrahydro-6-naphthyl)-1-propene
( E )-1-(2-carboxy-5-thienyl)-2-(1,4-methano-7-methyl1,2,3,4-tetrahydro-6-naphthyl)-1-propene (Z)-1-(2-carboxy-5-thienyl)-2-(1,4-methano-7-methyl1,2,3,4-tetrahydro-6-naphthyl)-1-propene ( E )-1-(4-carboxyphenyl)-2-(1,4-methano-7-methyl1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E ) -1-(4-carboxy-2-fluorophenyl)-2-(1,4-methano-7methyl-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxy-2-hydroxyphenyl)-2-(1,4-methano-7methyl-1,2,3,4-tetrahydro-6-naphthyl)-1-propene
(E)-1-(4-carboxy-2-methoxyphenyl)-2-(1,4-methano-7methyl-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxyphenyl)-1-fluoro-2-(1,4-methano1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxy-2-fluorophenyl)-l-fluoro-2-(1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxy-2-hydroxyphenyl)-1-fluoro-2-(1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene ( E )-1-(4-carboxy-2-methoxyphenyl)-1-fluoro-2-(1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E )-1-(4-carboxyphenyl)-l-fluoro-2-(l,4-methano-7methyl-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxy-2-fluorophenyl)-1-fluoro-2-(1,4methano-7-methyl-1,2,3,4-tetrahydro-6-naphthyl)-1propene (E)-1-(4-carboxy-2-hydroxyphenyl)-1-fluoro-2-(1,4methano-7-methyl-1,2,3,4-tetrahydro-6-naphthyl)-1propene (E)-1-(4-carboxy-2-methoxyphenyl)-1-fluoro-2-(1,4methano-7-methyl-1,2,3,4-tetrahydro-6-naphthyl)-1propene
(E)-1-(2-carboxy-5-thienyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1-propene (Z)-1-(2-carboxy-5-thienyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1-propene
(E)-1-(2-carboxy-5-thienyl)-2-(1,4-methano-7-methyl1,2,3,4-tetrahydro-6-naphthyl)-1-propene (Z)-1-(2-carboxy-5-thienyl)-2-(1,4-methano-7-methyl1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxyphenyl)-2-(1,4-dimethyl-1,4-methano1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxy-2-fluorophenyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxy-2-hydroxyphenyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene
(E)-1-(4-carboxy-2-methoxyphenyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(2-carboxy-5-pyridyl)-2-(1,4-dimethyl-1,4- . methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(2-carboxy-4-imidazolyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(2-carboxy-5-ρyrazinyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(2-carboxy-5-pyrimidinyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(2-carboxy-5-thienyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (Z)-1-(2-carboxy-5-thienyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxyphenyl)-1-fluoro-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene (E)-1-(4-carboxy-2-fluorophenyl)-1-fluoro-2-(1,4dimethyl-1,4-methano-1,2,3,4-tetrahydro-6-naphthyl)-1propene
(E)-1-(4-carboxy-2-hydroxyphenyl)-1-fluoro-2-(1,4dimethyl-1,4-methano-1,2,3,4-tetrahydro-6-naphthy1)-1propene
(E)-1-(4-carboxy-2-methoxyphenyl)-1-fluoro-2-(1,4dimethyl-1,4-methano-1,2,3,4-tetrahydro-6-naphthyl)-1propene
(E)-1-(4-carboxyphenyl)-1-fluoro-2-(1,4,7-trimethyl¬
1,4-methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene
(E)-1-(4-carboxy-2-fluorophenyl)-1-fluoro-2-(1,4,7trimethyl-1,4-methano-1,2,3,4-tetrahydro-6-naphthyl)¬
1-propene
(E)-1-(2-carboxy-5-thienyl)-2-(1,4,7-trimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene
(E)-1-(4-carboxy-2-hydroxyphenyl)-1-fluoro-2-(1,4,7trimethyl-1,4-methano-1,2,3,4-tetrahydro-6-naphthyl)¬
1-propene
(E )-1-(4-carboxy-2-methoxyphenyl)-1-fluoro-2-(1,4,7trimethyl-1,4-methano-1,2,3,4-tetrahydro-6-naphthyl)¬
1-propene (E)-1-(4-carboxyphenyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)ethene
(E)-1-(4-carboxy-2-fluorophenyl)-2-(1,4-methano¬
1,2,3,4-tetrahydro-6-naphthy1)ethene
(E)-1-(4-carboxy-2-hydroxyphenyl)-2-(1,4-methano1,2,3,4-tetrahydro-6-naphthyl)ethene
(E)-1-(4-carboxy-2-methoxyphenyl)-2-(1,4-methano¬
1,2,3,4-tetrahydro-6-naphthyl)ethene
(E)-1-(2-carboxy-5-pyridyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)ethene (E )-1-(2-carboxy-4-imidazolyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)ethene
(E)-1-(2-carboxy-5-pyrazinyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)ethene (E)-1-(2-carboxy-5-pyrimidiny1)-2-(1,4-methano1,2,3,4-tetrahydro-6-naphthyl)ethene (E )-1-(2-carboxy-5-thienyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)ethene (Z)-1-(2-carboxy-5-thieny1)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)ethene
(E)-1-(4-carboxyphenyl)-1-fluoro-2-(1,4-methano1,2,3,4-tetrahydro-6-naphthyl)ethene (E)-1-(4-carboxy-2-fluorophenyl)-1-fluoro-2-(1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E)-1-(4-carboxy-2-hydroxyphenyl)-1-fluoro-2-(1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E)-1-(4-carboxy-2-methoxyphenyl)-1-fluoro-2-(1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E )-1-(4-carboxyphenyl)-2-(1,4-dimethyl-1,4-methano1,2,3,4-tetrahydro-6-naphthyl)ethene
(E)-1-(4-carboxy-2-fluorophenyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E)-1-(4-carboxy-2-hydroxyphenyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E)-1-(4-carboxy-2-methoxyphenyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E)-l-(2-carboxy-5-pyridyl)-2-(1,4-diraethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene ( E )-1-(2-carboxy-4-imidazolyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene
(E)-1-(2-carboxy-5-pyrazinyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E )-1-(2-carboxy-5-pyrimidiny1)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E )-1-(2-carboxy-5-thieny1)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (Z)-1-(2-carboxy-5-thienyl)-2-(1,4-dimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (Z)-1-(2-carboxy-5-thienyl)-2-(1,4,7-trimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E )-1-(2-carboxy-5-thienyl)-2-(1,4,7-trimethyl-1,4methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E )-1-(4-carboxy-2-fluorophenyl)-2-(1,4,7-trimethyl1,4-methano-1,2,3,4-tetrahydro-6-naphthyl)ethene
(E )-1-(4-carboxy-2-hydroxyphenyl)-2-(1,4,7-trimethyl1,4-methano-1,2,3,4-tetrahydro-6-naρhthyl)ethene (E)-1-(4-carboxy-2-methoxyphenyl)-2-(1,4,7-trimethyl1,4-methano-1,2,3,4-tetrahydro-6-naρhthyl)ethene (E)-1-(4-carboxyphenyl)-1-fluoro-2-(1,4,7-trimethyl1,4-methano-1,2,3,4-tetrahydro-6-naphthyl)ethene (E )-1-(4-carboxy-2-fluorophenyl)-1-fluoro-2-(1,4,7trimethyl-1,4-methano-1,2,3,4-tetrahydro-6naphthyl)ethene (E)-1-(4-carboxy-2-hydroxyphenyl)-1-fluoro-2-(1,4,7trimethyl-1,4-methano-1,2,3,4-tetrahydro-6naphthyl)ethene
(E)-1-(4-carboxy-2-methoxyphenyl)-1-fluoro-2-(1,4,7trimethyl-1,4-methano-1,2,3,4-tetrahydro-6naphthyl)ethene
(E)-1-(4-carboxyphenyl)-2-(4,4-dimethyl-2,3-dihydro-1benzothiopyran-6-yl)-1-propene
(E)-1-(2-carboxy-5-pyridyl)-2-(4,4-dimethyl-2,3dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(2-carboxy-4-imidazolyl)-2-(4,4-dimethyl-2,3dihydro-1-benzothiopyran-6-yl )-1-propene
(E )-1-(2-carboxy-5-pyrazinyl)-2-(4, 4-dimethyl-2, 3dihydro-1-benzothiopyran-6-yl )-1-propene (E)-1-(2-carboxy-5-pyrimidinyl)-2-(4,4-dimethyl-2,3dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(2-carboxy-5-thienyl)-2-(4,4-dimethyl-2,3dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(4-carboxyphenyl)-2-(4,4,7-trimethyl-2,3dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(2-carboxy-5-pyridyl)-2-(4,4,7-trimethyl-2,3dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(2-carboxy-4-imidazolyl)-2-(4,4,7-trimethyl-2,3dihydro-1-benzothiopyran-6-yl)-1-propene
(E)-1-(2-carboxy-5-pyrazinyl)-2-(4,4,7-trimethyl-2,3dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(2-carboxy-5-pyrimidinyl)-2-(4,4,7-trimethyl2,3-dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(2-carboxy-5-thienyl)-2-(4,4,7-trimethyl-2,3dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(4-carboxyphenyl)-2-(4,4-dimethyl-2,3-dihydro-1benzopyran-6-yl)ethene (E)-1-(2-carboxy-5-pyridyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)ethene
(E)-1-(2-carboxy-4-imidazolyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)ethene
(E)-1-(2-carboxy-5-pyrazinyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)ethene (E)-1-(2-carboxy-5-pyrimidinyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)ethene (Z)-1-(2-carboxy-5-thienyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)ethene (E)-1-(4-carboxyρhenyl)-2-(4,4-dimethyl-2,3-dihydro-1benzothiopyran-6-yl)ethene
(E)-1-(2-carboxy-5-pyridyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)-propene
(E)-1-(2-carboxy-4-imidazolyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)-propene (E)-1-(2-carboxy-5-pyrazinyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)-propene
(E)-1-(2-carboxy-5-pyrimidinyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)-propene (Z)-1-(2-carboxy-5-thienyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)-propene
(E)-1-(4-carboxy-2-fluorophenyl)-2-(4,4-dimethyl-2,3dihydro-1-beήzothiopyran-6-yl)-1-propene (E )-1-(4-carboxy-2-fluorophenyl)-2-(4,4,7-trimethyl2,3-dihydro-1-benzopyran-6-yl)-1-propene
( E )-1-(4-carboxy-2-fluorophenyl)-2-(4,4-dimethyl-2,3dihydro-1-benzothiopyran-6-yl)ethene
(E)-1-(4-carboxy-2-fluorophenyl)-2-(4,4-dimethyl-2,3¬dihydro-1-benzopyran-6-yl)ethene (E )-1-(4-carboxy-2-fluorophenyl)-1-fluoro-2-(4,4,7trimethyl-2,3-dihydro-1-benzothiopyran-6-yl)-1-propene ( E )-1-(4-carboxy-2-fluorophenyl)-1-fluoro-2-(4,4dimethyl-2,3-dihydro-1-benzopyran-6-yl)-l-propene (E)-1-(4-carboxy-2-methoxyphenyl)-2-(4,4,7-trimethyl2,3-dihydro-1-benzopyran-6-yl)-1-propene
(E)-1-(4-carboxy-2-methoxyphenyl)-2-(4,4,7-trimethyl2,3-dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(4-carboxy-2-methoxyphenyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyrain-6-yl)ethene (E)-1-(4-carboxy-2-methoxyphenyl)-2-(4,4-dimethyl-2,3dihydro-l-benzothiopyran-6-yl)ethene (E)-1-(4-carboxy-2-methoxyphenyl)-1-fluoro-2-(4,4,7trimethyl-2,3-dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(4-carboxy-2-methoxyphenyl)-1-fluoro-2-(4,4dimethyl-2,3-dihydro-1-benzopyran-6-yl)-1-propene
(E)-1-(4-carboxy-2-hydroxyphenyl)-2-(4,4,7-trimethyl2,3-dihydro-1-benzothiopyran-6-yl)-1-propene (E)-1-(4-carboxy-2-hydroxyphenyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)-1-propene (E)-1-(4-carboxy-2-hydroxyphenyl)-2-(4,4-dimethyl-2,3dihydro-1-benzothiopyran-6-yl)ethene
(E)-1-(4-carboxy-2-hydroxyphenyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)ethene (E)-1-(4-carboxy-2-hydroxyphenyl)-1-fluoro-2-(4,4dimethyl-2,3-dihydro-l-benzopyran-6-yl)-1-proρene (E )-1-(4-carboxy-2-hydroxyphenyl)-1-fluoro-2-(4,4dimethyl-2,3-dihydro-1-benzothiopyran-6-yl)-1-propene
Examples of esters (R = alkoxy, aroxy) are the methyl, ethyl, isopropyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, hydroxymethyl, 2hydroxyethyl, 3 hydroxypropyl, phenyl, p-hydroxyphenyl, o-hydroxyphenyl, p-methoxyphenyl, tolyl, and naphthyl esters of the above acids. Examples of carboxamides ( R = NR5R6) are the N-methyl, N-isopropyl, N-hexyl, N-octyl, N-2hydroxyethyl, N-3-hydroxypropyl, N,N-dimethyl, Nphenyl, N-p-hydroxyphenyl, N-p-methoxyphenyl, and N-pethoxyphenyl carboxamides of the above acids and esters.
The retinoids of formula (1) where X, X1, R1, R3 and R4 are hydrogen, R2 is methyl, the fused ring group is a benSsonorbornene and Q is carboxyphenyl
or carbethoxyphenyl may be made by the following route:
Figure imgf000017_0001
Ac = H3CC(O)-
Other esters and esters of the other aromatics may be made by starting with the desired phosphonate of the appropriate aromatic carboxyl ester. The carboxamides may be made from the acids by conversion to acid chlorides or activated esters followed by reaction with an appropriate amine.
The preparation of the fluoro, methyl, methoxy and hydroxy substituted benzonorbornenyl retinoids may also be achieved using this same type of synthesis scheme:
Figure imgf000018_0002
15-crown-5 = 1,4,7,10,13-pentaoxacyclopentadecane and THF = tetrahydrofuran.
The dihydrobenzothiopyranyl retinoids of formula 1 may be made by the following schemes:
Figure imgf000018_0001
Ac = H3CC(O)-, THF = tetrahydrofuran, and 15-crown-5 = 1,4,7,10,13-pentaoxacyclopentadecane.
According to the following method the dihydrobenzopyrans are made analogously from the oxygen analog of 2,3-dihydro-4,4-dimethyl-1benzothiopyran (compound 5 in the above scheme):
Figure imgf000019_0001
Where the abbreviations are as above. An alternative method (Method B) for preparing 2,3-dihyd'ro-4,4-dimethyl-1-benzopyran (compound 12 in the above scheme) is as follows:
(1) Butsugan, Y., et al, Chem Lett (1976) 523.
(2) Chatelus, G., Ann Chim (1949) 4:505.
Figure imgf000020_0001
As in the case of the benzonorborene compounds other esters and esters of other aromatics of the benzopyran and benzothiopyran compounds may be made by varying the phosphonate reactant.
The following examples further illustrate the invention compounds and their preparation. These examples are not intended to limit the invention in any manner. Abbreviations used in the examples are Me = methyl, Et = ethyl, Bu = butyl. NBS = N-bromosuccinimide, Ac = H3CC(O)-, LDA = lithio diisopropylamide, THF = tetrahydrofuran, LC = high-performance liquid chromatography, IR = infrared, NMR = nuclear magnetic resonance, UV = ultraviolet, EMF = dimethylformamide, GC = gas chromatography, TLC = thin layer
(3) Milstien, S., et al, J Amer Chem Soc (1972) 94:9158.
(4) Borchardt, R.T., et al, J Amer Chem Soc (1972) 94:9166. chromatography, Pd/C = palladium on carbon, and 15crown-5 = 1,4,7,10,13-pentaoxacyclopentadecane.
Example 1. Preparation of (E)-1-(4-Carboethoxyphenyl)-2-(1,4 methano-1,2,3,4-tetrahydro-6- naphthyl)-1-propene and (E )-1-(4-Carboxypheny1)¬
2-(1,4 methano-1,2,3,4-tetrahydro-6-naphthyl)-1propene
1,4-Methano-1,4-dihydronaphthalene. Cyclopentadiene (bp 39-40ºC) was prepared by heating the dimer and distilling twice through a 10-cm Vigreaux column packed with glass helices. It was stored at -78ºC before use. To 4.0 g (0.166 mol) of powdered Mg (20 to 100 mesh) was added 10 mL of a solution of 26 g (0.15 mol) of o-fluorobromobenzene and 9.8 g (0.15 mol) of cyclopentadiene in 90 mL of THF. The reaction started instantaneously. The remaining solution was added dropwise over a period of 45 min to maintain a gentle reflux. When the addition was complete, the mixture was stirred for another 45 min at room temperature. It was then diluted with 50 mL of THF and filtered. The filtrate was concentrated to a small volume and about 150 mL of saturated NH4Cl was added. The product was extracted with Et2O (3 x 100 mL). The Et2O layer was dried (Na2SO4) and evaporated to give 16 g of a yellow oil. This oil was distilled at 50-54ºC (1.75 mm) to give 10.7 g of the product, which was still contaminated with some polar impurities by TLC. The distillate was passed over 200 g of SiO2 (5% Et2O/hexane) to give 10.2 g of product as a yellow oil (48% yield): IR (film) 3080, 3000, 2950, 2890, 1460, 1310, 1240, 1020, 840, 760, 730, 700 cm-1; 1H MIR (CDCI3) δ 2.27 (s, 2, CH2), 3.83 (m, 2, CH), 6.8-7.4 (m, 6, HC=CH, ArH); MS calculated for C11H10142.0782, found 142.0781.
1,4-Methano-1,2,3,4-tetrahydronaphthalene. To 16.0 g (0.113 mol) of the purified 1,4-methano-1,4-dihydronaphthalene in 150 mL of absolute EtOH was added 1.0 g of 5% Pd/C. This mixture was hydrogenated at room temperature and atmospheric pressure. After about 20 h, TLC indicated that no starting material remained. The reaction mixture was filtered, concentrated and distilled to afford 10.0 g (62% yield) of the product as a colorless oil: bp 67ºC (4.5 mm): IR (film) 3070, 3030, 2980, 2880, 1490, 1470, 1320, 1300, 1260, 1160, 1120, 1080, 1020, 960, 940, 880, 840, 760, 720 cm-1; 1H NMR (CDCI3) δ 1.1-1.5 (m, 2, HCCH2CH), 1.5-2.1 (m, 4, (CH2)2), 3.35-3.5 (m, 2, CH), 7.0-7.3 (m, 4, ArH); MS calcd for C11Hl2 144.0939, found 144.0930.
6-Acetyl-1,4-methano-1,2,3,4-tetrahydronaphthalene. A mixture of 6.9 g (47.9 mmol) of 1,4-methano-1,2,3,4tetrahydronaphthalene and 4.14 g (52.7 mmol) of AcCl was added dropwise over a period of 20 min to a stirred suspension of 7.34 g (55 mmol) of AlCl3 in 50 mL of ClCH2CH2Cl, which was cooled in a water bath at 20ºC . When the addition was complete, the mixture was stirred at room temperature for 1 h. The reaction was quenched with 100 mL of ice-water and extracted with Et2O (2 x 150 mL). The Et2O layer was dried and concentrated to give 10.6 g of a yellow oil. Distillation gave 8.1 g (91% yield) of the product as a pale yellow oil, bp 102ºC (0.2 mm): IR (film) 3000, 2900, 1690, 1630, 1590, 1440, 1370, 1310, 1280, 1200, 1160, 1120, 1030, 960, 920, 850, 840 cm-1; 1H NMR (CDCl3) δ 1.05-1.3 (m, 2, CHCH2CH), 1.4-2.1 (m, 4, (CH2)2), 2.57 (s, 3, CH3CO), 3.3-3.5 (m, 2, CH), 7.27 (d, J = 8 Hz, 1, 8-ArH), 7.77 (dd, J = 2 Hz, J = 8 Hz, 1, 7-ArH), 7.83 (d, J = 2 Hz, 1, 5-ArH); MS calcd for C13H14O 186.1045, found 186.1036.
(E )-1-(4-Carbethoxyphenyl)-2-(1,4-methano¬
1,2,3,4-tetrahydro-6-naphthyl)-1-propene and (Z)-1-(4¬
Carbethoxyphenyl)-2-(1,4-methano-1,2,3,4-tetrahydro-6- naphthyl)-1-propene. Diethyl 4-carbethoxybenzylphos- phonate was prepared in 76% yield. (5) A solution of 13.8 g (46 mmol) of this phosphonate in 150 mL of THF was cooled to -20ºC while 30 mL (45.6 mmol) of a 1.52 M solution of n-BuLi in hexane was added over a period of 15 min. The dark brown solution was warmed up to 0°C and 8.6 g (46.2 mmol) of 6-acetyl-1,4-methano1,2,3,4-tetrahydronaphthalene in 10 mL of THF was added. The mixture was stirred at room temperature for 16 h. The reaction mixture was next poured onto 500 mL of ice-water and extracted with Et2O (3 x 200 mL). The Et2O layer was dried (Na2SO4) and concentrated to give about 20 g of a yellow oil. This oil was partially purified on 150 g of silica gel (7% Et2O/hexane) to give 3.0 g of the unreaσted starting material, 6-acetyl-1,4-methano-1,2,3,4-tetrahydronaphthalene, and 7.0 g (70% yield from the amount of ketone consumed) of an approximately 2:1 mixture of Z and E isomers, (Z)-1-(4-carbethoxyphenyl)-2-(1,4methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene and (E)-1-(4-carbethoxyphenyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthyl)-1-ρropene, respectively. A purification of the mixture by LC (1% Et2O/hexane)
(5) Kreutzkamp, N. and Cordes, G., Arch Pharm (1961) 294:49. gave 3.0 g of a mixture containing over 90% of the Z isomer and 3.5 g of a 1:1 mixture of Z and E isomers. A solution of 3.0 g of the 9:1 Z/E mixture in 500 mL of CH2Cl2 was irradiated with a mediumpressure Hanovia Hg-arc lamp for 5 h to give a 1:1 mixture of the Z and E isomers. The combined mixtures were purified by multiple passes on LC (1% Et2O/hexane) to give 2.0 g (20%) of the E isomer (E)1-(4-carbethoxyphenyl)-2-(1,4-methano-1,2,3,4-tetrahydro-6-naphthyl)-1-propene and 2.1 g (21%) of the Z isomer, (Z)-1-(4-carbethoxyphenyl)-2-(1,4-methano1,2,3,4-tetrahydro-6-naphthyl)-1-propene. E-isomer: LC (Radialpak B, 2% Et2O/hexane, 3 mL/min, 260 nm) tR 5.0 min (0.5%), 5.7 min (99.5%); LC (Radialpak A, 5% H2O/MeCN, 2 mL/min, 260 nm) tR 6.2 min (100%); IR
(film) 3000, 2900, 1730, 1620, 1580, 1490, 1460, 1420, 1380, 1290, 1190, 1110, 1030, 960, 890, 830, 770, 750, 710 cm-1; 300 MHz 1H NMR (CDCl3) δ 1.15-2.30, 1.501.60, and 1.90-2.00 (3 m, 6, (CH2)2, HCCH2CH), 1.41 (t, J = 7 Hz, 3, CH2CH3). 2.29 (s, 3, CH3), 3.37 (s, 2, CH), 4.38 (q, J = 7 Hz, 2, CO2CH2CH3), 6.81 (s, 1, C=CH), 7.16 (d, J = 8 Hz, 1, 8-ArH), 7.24 (d, J = 8 Hz, 1, 7-ArH), 7.35 (s, 1, 5-ArH), 7.40 (d, J = 8Hz, 2, 2',6'-H), 8.03 (d, J = 8 Hz, 2, 3',5'-H); 13C NMR (CDCl3) 14.3 (CH2CH3), 17.8 (C=CCH3), 27.0 ((CH2)2), 43.4 (HCCH2CH), 43.8, 49.2 (CH), 60.7 (CH2CH3), 118.2, 120.2, 123.3, 125.8, 128.0, 128.9 and 129.3 (C-2,,3,,5,,6'), 140.1, 141.0, 143.3, 147.8, 148.3, 166.4 ppm (CO2); UV (EtOH) λmax308 nm (ε 2.66 x 104), 233 nm (ε 1.49 x 104), 206 nm (ε 2.68 x 104); MS calcd for C23H24O2 332.1776, found 332.1757. Z-isomer: LC (Radialpak B, 2% Et2O/hexane, 3 mL/min, 260 nm) tR 5.0 min (99%), 5.7 min (1%); LC (Radialpak A, 5% H2O/MeCN, 2 mL/min, 260 nm) tR 5.9 min (100%); IR (film) 3000, 2900, 1730, 1620, 1580, 1490, 1460, 1420, 1380, 1290, 1190, 1110, 1030, 960, 890, 830, 770, 750, 710 cm"1; 300 MHz 1H NMR (CDCl3) δ 1.10-1.20, 1.45-1.55 and 1.80-1.90 (3 m, 6, (CH2)2, HCCH2CH), 1.35 (t, J = 7 Hz, 3, CH2CH3), 2.21 (s, 3, C=CCH3), 3.25 and 3.34 (2 s, 2, CH), 4.34 (q, J = 7 Hz, 2, CH2CH3), 6.42 (s, 1, C=CH), 6.85 (d, J = 8 Hz, 1, 7-ArH), 6.94 (s, 1, 5- ArH), 6.95 (d, J = 8 Hz, 2, 2',6'-H), 7.06 (d, J = 8 Hz, 1, 8-ArH), 7.73 (d, J = 8 Hz, 2, 3', 5' -H); 13C NMR (CDCl3) 14.3 (CH2CH3 ), 27.1 ((CH2)2), 27.5 (C=CCH3), 43.5 (HCCH2CH), 43.7 and 49.1 (CH), 60.6 (CH2CH3), 120.1, 120.5, 124.9, 125.2, 127.6, 128.6 and 128.9 (2',3',5',,6'), 138.7, 142.5, 142.7, 147.4,
148.5, 166.5 ppm (CO2); UV (EtOH) λmax 300 nm (ε 1.68 x 104), 239 nm (ε 1.67 x 104), 205 nm (ε 2.89 x 104); MS calcd for for C23H24O2 332.1776, found 332.1741.
(Z)-1-(4-Carboxyphenyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthy1)-1-propene. To a solution of 1.8 g (5.42 mmol) of the Z-ester in 20 mL of warm EtOH was added a solution of 1.5 g of KOH (26.7 mmol) in 2 mL of H2O and 3 mL of EtOH. The mixture was degassed three times under argon and heated in an 80°C oil bath for 30 min. The cooled solution was acidified with 20 mL of 50% H2O/HOAc. The precipitated acid was extracted into 100 mL of Et2O. The Et2O layer was washed with 100 mL of brine, dried (MgSO4), and evaporated. The crude acid was recrystallized from MeOH to give 1.3 g (79% yield) of (Z)-1-(4-carboxyphenyl)-2-(1,4 methano-1,2,3,4-tetrahydro-6naρhthyl)-1-propene as white crystals, mp 188°C: LC (Radialpak A, reverse phase, 40% H2O/CH3CN, 2 mL/min, 260 nm) tR 1.3 min (100%); IR (mull) 1690, 1610, 1320, 1300, 1180, 1120, 940, 880, 830, 770, 730, 700 cm-1; 300 MHz 1H NMR (CDCl3) δ 1.10-1.30, 1.45-1.55 and 1.80-1.95 (3 m, 6, (CH2)2, HCCH2CH), 2.23 (s, 3, CH3), 3.25 and 3.34 (2 s, 2, CH) , 6.44 (s, 1, C=CH), 6.86 (d, J = 8 Hz, 1, 7-ArH), 6.94 (s, 1, 5-ArH), 6.97 (d, J = 8 Hz, 2, 2', 6' -H), 7.08 (d, J = 8 Hz, 1, 8-ArH), 7.77 (d, J = 8 Hz, 2, 3', 5'-H) 9.5-10.4 (broad s, 1, CO2H); 13C NMR (CDCl3/Me2SO-d6) 26.9 ((CH2)2), 27.2 (C=CCH3), 43.3 (HCCH2CH), 43.4 and 48.9 (CH), 119.9, 120.3, 124.7, 125.0, 127.3, 128.5 and 129.1 (2,,3,,5',6'), 138.4, 142.3, 142.7, 147.2, 148.3,
169.4 ppm (CO2); UV (EtOH) λmax 293 nm (ε 1.43 x 104), 280 nm (ε 1.39 x 104), 238 nm (ε 1.44 x 104); MS calcd for C21H20O2 304.1463, found 304.1436.
(E)-1-(4-Carboxypheny1)-2-(1,4-methano-1,2,3,4tetrahydro-6-naphthy1)-1-propene. A solution of 1.5 g (26.7 mmol) of KOH in 2 mL of H2O and 3 mL of EtOH was added, to a warm solution of 2.0 g (6.02 mol) of (E)-1(4-carbethoxyphenyl)-2-(1,4-methano-1,2,3,4tetrahydro-6-naρhthyl)-1-propene in 20 mL of EtOH. The mixture was degassed under argon three times and then heated at 80ºC for 30 min, cooled and acidified with 20 mL of 50% H2O/HOAc. The acid was extracted with 100 mL of Et2O. The Et2O solution was washed with 100 mL of brine, dried (MgSO4), and concentrated to give 1.8 g of the crude acid, which was recrystallized from EtOAc to afford 1.2 g (66% yield) of white crystals, mp 209'C: LC (Radialpak A, 40% H2O/MeCN, 2 mL/min, 260 nm) tR 1.25 min (100%); IR (mull) 1690, 1610, 1320, 1300,.1180, 1120, 960, 890, 830, 720 cm"1; 300 MHz 1H NMR (CDCl3) δ 1.20-1.30, 1.50-1.60 and
1.85-1.95 (3 m, 6, (CH2)2, HCCH2CH), 2.31 (s, 3, CH3), 3.38 (s, 2, CH), 6.82 (s, 1, C=CH), 7.16 (d, J = 8 Hz, 1, 8-ArH), 7.25 (d, J = 8 Hz, 1, 7-ArH), 7.36 (s, 1, 5-ArH), 7.45 (d, J = 8 Hz, 2, 2',6'-H), 8.08 (d, J = 8 Hz, 2, 3',5'-H), 8.4-9.0 (broad s, 1, CO2H); 13C NMR (CDCl3/Me2SO-d6) 17.7 (CH3), 26.8 ((CH2)2), 43.2 (HCCH2CH), 43.6 and 49.0 (CH), 118.0, 120.0, 123.1, 125.7, 128.7 and 129.4 (2',3',5',6'), 139.8, 140.8, 142.9, 147.6, 148.2, 168.4 ppm (CO2); UV (EtOH) λmax 301 nm (ε 2.45 x 104), 227 nm (ε 1.35 x 104); MS calcd for C21H20O2 304.1463, found 304.1451.
Example 2. Preparation of (E)-1-(4-Carbethoxyphenyl)2-(4,4-dimethyl-2,3-dihydro-1-benzothiopyran-6-yl)¬
1-propene and (E)-1-(4-Carboxyphenyl)-2-(4,4-dimethyl¬
2,3-dihydro-1-benzothiopyran-6-yl)-1-propene.
Phenyl 3,3-Dimethylthiolacrylate. To a degassed (argon) suspension of -NaH, which was obtained from 3.2 g (80 mmol) of 60% NaH/mineral oil dispersion, which had been washed with hexane (3 x 15 mL) under argon, in 30 mL of THF, was added over a period of 5 min with stirring and cooling in ice a solution of 8.8 g (80 mmol) of thiophenol in 80 mL of THF. The suspension was stirred for a further 15 min and then treated with a solution of 10.1 g (85 mmol) of 3,3dimethylacryloyl chloride in 40 mL of THF over a period of 10 min and then allowed to warm to room temperature over a 2-h period. The suspension was poured into 200 mL of water containing 2 mL of HOAc and stirred for 15 min and then extracted with 200 mL of Et2O. The extract was washed with dilute brine (3 x 100 mL), dried (Na2SO4), and concentrated to give a yellow oil. Distillation yielded the thiolester, phenyl 3,3-dimethylthiolacrylate, as 15.0 g (98% yield) of colorless liquid, bp 105-106"C (0.7 mm); IR (CHCl3) 1680, 1625, 1475 cm-1; 1H NMR (CDCl3) δ 1.88, 2.14 (2 s, 6, (CH3)2C), 6.07 (m, 1, C=CH), 7.43 (m, 5, ArH); MS calcd for C11H12OS 192.061, found 192.059.
2,3-Dihydro-4,4-dimethyl-2-oxo-1-benzothiopyran. A stirred, ice-cooled suspension of 14.0 g (105 mmol) of AlCl3 in 100 mL of CH2Cl2 was treated with a solution of 13.44 g (70 mmol) of phenyl 3, 3-dimethylthiolacrylate in 70 mL of CH2Cl2. The reaction mixture was allowed to stand at 0ºC for 15 h and then was poured onto 200 g of ice/brine. The aqueous phase was extracted with 100 mL of CH2Cl2. The combined CH2Cl2 solutions were washed with dilute brine (2 x 150 mL) and water (150 mL), dried (Na2SO4), and concentrated. The pale yellow liquid (13.5 g) was chromatographed on a 7 x 35-cm column of silica gel (10% Et2O/hexane) to give 12.24 g (91% yield) of the thiolactone, 2,3-dihydro-4,4-dimethyl-2-oxo-1-benzothiopyran, as a solid, mp 34-35ºC; IR (CHCl3) 1680, 1595, 1475 cm-1; 1H NMR (CDCl3) δ 1.39 (s, 6, (CH3)2C), 2.65 (s, 2, CH2CO), 7.15-7.63 (m, 4, ArH); MS calcd for C11H12OS 192.061, found 192.059.
2,3-Dihydro-4,4-dimethyl-1-benzothiopyran. Method A. To 1.0 g (26 mmol) of LiAlH4, which was stirred under argon in an ice bath, was added 15 mL of THF. This suspension was degassed twice with argon. A solution of 0.96 g ( 5.0 mmol) of 2 , 3-dihydro-4,4dimethyl-2-oxo-1-benzothiopyran in 6 mL of THF was introduced dropwise at room temperature. The reaction mixture was then refluxed for 4 h, cooled in ice/water, and the excess LiAlH4 was quenched by the dropwise addition of 20% EtOAc/THF. The mixture was poured onto 50 mL of 2 N H2SO4 and extracted with 2 x 25 mL of Et2O. The extract was washed with diluted brine (3 x 25 mL), dried (Na2SO4), and concentrated. The colorless oil (0.95 g) was chromatographed on a 2 x 30-cm silica gel column, which was eluted with 350 mL of 2% Et2O/hexane, to give, successively, (a) 0.36 g (40% yield) of 2,3-dihydro-4,4dimethy1-1-benzothiopyran, as a colorless liquid: IR (CHCl3) 1595, 1470 cm-1; 1H NMR (CDCl3) δ 1.29 (s, 6, (CH3)2C), 1.90 (m, 2, CCH2), 2.98 (m, 2, CH2S), 6.87 (m, 3, ArH), 7.27 (m, 1, ArH); MS calcd for C11H14S 178.081, found 178.080; and (b) 0.51 g (52% yield) of the alcohol (compound 4 on page 15) as a colorless gum: IR (CHCl3) 3600, 3430, 1590 cm-1; 1H NMR (CDCl3) δ 1.47 (s, 6, (CH3)2C), 2.12 (broad s, l, OH, exchanged D2O), 2.23 (t, J = 8 Hz, 2, CCH2), 3.38 (t, J = 8 Hz, 2, CH2O), 3.60 (broad s, 1, SH, exchanged D2O), 6.90-7.38 (m, 4, ArH); MS calcd for C11H16OS 196.092, found 196.089.
Method B: To a solution of 22.9 g (88 mmol) of SnCl4 in 200 mL of CH2Cl1, cooled in ice, was added a solution of 7.83 g (44 mmol) of 3-methyl-2-buten-1-yl phenyl sulfide in 40 mL of CH2Cl2. The solution was stirred at 0-5ºC for 20 min and then at room temperature for 20 h. The red solution was poured onto 500 g of ice/brine,' and the organic extract was washed successively with 250-mL volumes of brine, aqueous
NaHC03, and water (three times). The CH2Cl2 solution, which contained suspended inorganic material, was dried (Na2SO4), filtered, and concentrated. The 7.4 g of yellow liquid was chromatographed twice using a 4.5 x 40-cm silica gel column with 0.75% Et2O/hexane to give 4.11 g (52% yield) of 2,3-dihydro-4,4dimethyl-1-benzothiopyran, a colorless liquid. The product was spectrally (IR, NMR) identical with the sample prepared by the LiAlH4 reduction of 2,3-dihydro-4,4-dimethyl-2-oxo-1-benzothiopyran. 3-Methyl-2-buten-1-yl Phenyl Sulfide. A stirred suspension of NaH, which was obtained by washing (hexane, 3 x 15 mL) 3.0 g (75 mmol) of 60% NaH/mineral oil dispersion under argon, in 20 mL of THF was cooled under argon in ice/water and treated with 7.15 g (65 mmol) of thiophenol in 65 mL of THF, which was added dropwise over a 10-min period. The suspension was stirred for 40 min before a solution of 9.3 g (62.4 mmol) of 3,3-dimethylallyl bromide in 25 mL of THF was added over a 10-min period, while the reaction mixture was maintained at ice-bath temperature. The reaction mixture was stirred for a further 45 min and then allowed to warm to room temperature over a 1.25-h period. The white suspension was poured into 300 mL of water. The organic phase was washed with 150 mL of 1 N NaOH solution and twice with 150 mL of dilute brine and dried (Na2SO4, overnight). The colorless solution was concentrated, and the resulting oil was chromatographed on a 5 x 40-cm silica gel column with 2 L of hexane, followed by 1% Et2O/hexane. The crude allylic sulfide, 3-methyl-2-buten-1-yl phenyl sulfide, was obtained as a colorless oil (10.3 g). This oil was distilled to give 9.76 g (88% yield) of 3-methyl2-buten-l-yl phenyl sulfide as a colorless, foulsmelling liquid, bp 83-85ºC (0.8 mm); IR (CHCl3) 1665, 1580, 1475 cm-1; 1H SMR (CDCl3) δ 1.57, 1.70 (2 s, 6, (CH3)2C), 3.52 (d, J = 8 Hz, 2, CH2S), 5.30 (t, J = 8 Hz, 1, C=CH), 7.28 (m, 5, ArH); MS calcd for C11H14S 178.081, found 178.080. 6-Acetyl-2,3-dihydro-4,4-dimethyl-1-benzothiopyran. A solution of 1.3 g (16.6 mmol) of acetyl chloride and 2.85 g (16.0 mmol) of 2,3-dihydro-4, 4-dimethyl-1benzothiopyran in 50 mL of CS2 was added dropwise over a 15-min period to 3.2 g (24.0 mmol) of AlCl3 with stirring and cooling in ice. The additon funnel was rinsed with 10 mL of CS2. The reaction mixture was stirred at room temperature for 2.25 h, before the resultant orange suspension was treated with 50 mL of ice/brine. The organic phase was separated, and the aqueous phase was extracted with CH2Cl2 (2 x 50 mL). The combined extracts were washed with dilute brine (3 x 50 mL), dried (Na2SO4), and concentrated. The pale yellow, viscous oil was chromatographed on a 3 x 30-cm silica gel column with 10% Et2O/hexane to give 2.92 g (83% yield) of 6-acetyl-2,3-dihydro-4,4dimethyl-1-benzothiopyran as a pale yellow, viscous liquid; IR (CHCl3) 1670, 1590, 1545 cm"1; 1H NMR (CDC13) δ 1.35 (s, 6, (CH3)2C), 1.93 (m, 2, CCH2 ) , 2.53 (s, 3, CH3CO), 3.05 (m, 2, CH2S), 7.12 (d, J =
8. 5 Hz , 1 , 8-ArH) , 7. 57 (dd, J = 8. 5, 2 Hz , 1 , 7-ArH ) , 8. 00 (d, J = 2 Hz , 1 , 5-ArH ) ; UV (MeCN) λmax 237. 5 nm ( ε 6. 3 x 103 ) , 242 nm ( ε 6. 2 x 103 ) , 310 nm ( ε 1.82 x 104 ) ; MS calcd for C1 3H16OS 220.092, found 220.090.
(E)-1-(4-Carbethoxyphenyl)-2-(4,4-dimethyl-2,3dihydro-1-benzothiopyran-6-yl)-1-propene. To a suspension of NaH, which was obtained from 0.52 g (13 mmol) of 60% NaH/mineral oil dispersion washed three times with 2 mL of hexane, in 20 mL of THF under argon was added at room temperature over a period of 50 min a solution of 2.2 g (10.0 mmol) of 6-acetyl2,3-dihydro-4,4-dimethyl-1-benzothiopyran, 3.6 g (12.0 mmol) of diethyl 4-carbethoxybenzyl phosphonate, and 0.45 g (2.0 mmol) of 15-Crown-5 in 30 mL of THF. The orange suspension was stirred at room temperature for 17 h to give a red solution and a red-orange gum. This mixture was treated with 200 g of ice/brine containing 1 mL of HOAc and extracted with Et2O (2 x 50 mL). The extract was washed with 50 mL of dilute brine, dried (Na2SO4), and concentrated. The yellow solid was chromatographed on a 3 x 30-cm silica gel column with 7% Et2O/hexane to give 3.2 g (87% yield) of the crude product, which was further purified by preparative LC in 7% Et2O/hexane to give 3.14 g (85% yield) of (E)-1-(4-carbethoxyphenyl)-2(4,4-dimethyl-2,3-dihydro-1-benzothiopyran-6-yl)-1propene. H NMR and analytical LC (Radialpak B, 5% Et2O/hexane, 1 mL/min, 280 nm) indicated a single isomer contaminated with an oxidation product. Two crystallizations from 20 to 30 mL of 10% EtOAc/hexane gave 1.70 g (46% yield) of the pure E-ester (E)-1-(4carbethoxyphenyl)-2-(4,4-dimethyl-2,3-dihydro-1benzothiopyran-6-yl)-1-propene, mp 94-94.5ºC. A further 0.56 g (15% yield) was obtained by two more crystallizations of the material recovered from the crystallization mother liquor. The combined yield of white crystals was 2.26 g (62%); LC (Radialpak A,
MeCN, 1 mL/min, 280 nm) tR 7.8 min (100%); LC (Radialpak B, 5% Et2O/hexane, 1 mL/min, 280 nm) tR 7.3 min (100%); IR (CHCl3) 1705, 1605, 1475 cm-1; 1H NMR (CDCl3) δ 1.38 (s, 6, (CH3)2C), 1.41 (t, J = 7 Hz, 3,
CH2CH3), 1.99 (m, 2, CCH2) 2.27 (d, J = 1 Hz, H3CC=C), 3.05 (m, 2, CH2S), 4.39 (q, J = 7 Hz,
CH2CH3), 6.79 (s, 1, C=CH), 7.09 (d, J = 8 Hz, 1, 8¬
ArH), 7.21 (dd, J = 8 Hz, J = 2 Hz, 1, 7-ArH), 7.41
(d, J = 8 Hz , 2 , ArH m to CO 2Et) 7. 51 (d, J = 2 Hz, 1 , 5-ArH), 8.04(d, J = 8 Hz, 2, ArH o to CO2Et); 13C NMR (CDCl3) 14.3, 17.6, 23.1, 30.2, 33.1, 37.7, 60.7, 123.5, 123.8, 125.5, 126.2, 128.0, 128.7, 129.2, 131.2, 139.1, 139.1, 141.5, 142.8, 166.1 ppm; UV (EtOH) λmax 244.5 nm (ε 1.24 x 104), 326 nm (ε
2.62 x 104); MS calcd for C23H26O2S 366.165, found 366.163.
(E)-1-(4-Carboxyphenyl)-2-(4,4-dimethyl-2,3-dihydro¬
1-benzothiopyran-6-yl)-1-propene. To a degassed (three times, argon) suspension of 1.50 g (4.1 mmol) of the ethyl ester (E)-1-(4-carbethoxyphenyl)-2-(4,4dimethyl-2,3-dihydro-1-benzothiopyran-6-yl)-1-propene in 7.5 mL of EtOH was added a degassed (two times, argon) solution of 0.75 g (11.4 mmol) of 85% KOH in 2.25 mL of water, followed by a 0.5-mL water rinse.
The mixture was again degassed (twice) and then heated at reflux in a 100-110ºC oil bath for 40 min. The ester dissolved within 15 min to give a pale-yellow solution. The reaction mixture was cooled to room temperature, quenched with a solution of 2 mL of HOAc in 10 mL of water, and then diluted with 10 mL of brine. Because the white, solid carboxylic acid failed to dissolve in Et2O, it was extracted out with EtOAc (100 mL, then 50 mL). The very pale-yellow extract was washed with dilute brine (2 x 25 mL) and water (25 mL), dried (Na2SO4), and concentrated. The almost white powder was recrystallized twice from 60 mL of EtOAc to give 1.05 g (75% yield) of white crystals, mp 217-217.5°C: LC (Radialpak A, 40% H2O/MeCN, 1 mL/min, 280 nm) tR 1.6 (0.3%), 2.1 (1.5%), 4.3 min (98.2%); IR (mull) 3200-2200, 1680, 1600 cm-1; lH NMR (CDCl3) δ 1.38 (s, 6, (CH3)2C), 1.99 (m, 2, CCH2), 2.29 (s, 3, H3CC=C), 3.05 (m, 2, CH2S), 6.80 (s, 1, C=CH), 7.10 (d, J = 8.6 Hz, 1, 8-ArH), 7.22 (dd, J = 8.3, J = 1.7 Hz, 1, 7-ArH), 7.46 (d, J = 8.3 Hz, 2, ArH m to CO2H), 7.52 (d, J = 1.8 Hz, 1, 5ArH), 8.11 (d, J = 8.3 Hz, 2, ArH o to CO2H); 13C EMR (CDCl3/Me2SO-d6) 16.5, 21.8, 29.0, 31.9, 36.4, 122.3, 122.7, 124.3, 125.0, 127.4, 127.6, 128.2, 130.0, 137.7, 138.8, 140.4, 141.3, 166.4 ppm; UV (EtOH) λmax 233 nm (ε 1.08 x 104), 319 nm (ε 2.53 x 104); MS calcd for C21H22O2S 338.134, found 338.132.
Example 3. Preparation of (E)-1-(4-Carboxyphenyl¬
2-(4,4 dimethyl-2,3-dihydro-1-benzopyran-6-yl)-1propene.
2,3-Dihydro-4,4-dimethyl-1-benzopyran was prepared by two routes, both based on reported procedures. Method A as shown on page 16 utilized a Friedel-Crafts alkylation of phenol by diphenyl 3-methyl-3-buten-1-yl phosphate (Butsugan Y., et al, supra). The overall yield from diphenyl chlorophosphate was 39%. Method B as shown on page 17 employed an intramolecular Friedel-Crafts alkylation (Milstien, S., et al, supra) of phenyl 3,3-dimethylacrylate to give the lactone, 2,3-dihydro-4,4-dimethyl-2-oxo-1-benzopyran, which was reduced to the diol (compound 18 on page 17, Borchardt, R.T., et al, supra), and the primary alcohol group of which was selectively esterified as the mesylate. Intramolecular displacement of the mesylate by phenoxide ion gave 2,3-dihydro-4,4dimethyl-1-benzopyran in 71% overall yield from phenol. Attempted synthesis of 2,3-dihydro-4,4dimethyl-1-benzopyran by cyclization of 3, 3-dimethylallyl phenyl ether using a variety of Lewis acids gave little or none of the desired ether. 2,3-Dihydro-4,4 dimethyl-1-benzopyran was readily and cleanly acetylated at the 6-position in 81% yield using acetyl chloride and SnCl4. Acylation of chroman at C-6 is well established (Chatelus, G., supra).
The olefin (E)-1-(4-carbethoxyρhenyl)-2-(4,4-dimethyl2,3-dihydro-1-benzopyran-6-yl)-1-propene was prepared from 6-acetyl-2,3-dihydro-4,4-dimethyl-1-benzopyran by Horner-Emmons reaction using diethyl 4-carbethoxybenzyl phosphonate in the presence of 15Crown-5 at room temperature. Surprisingly, the reaction was not completely stereoselective. (6) The major, E-isomer was easily isolated in 57% yield by crystallization from hexane. A sample of the minor isomer was obtained by recycle LC (5% Et2O/hexane) for spectral comparison. The 1H NMR spectrum of the minor isomer showed significant upfield shifts of the chroman aromatic protons (unresolved multiplets at 60 MHz) and of the gem-dimethyl protons (upfield shift of the minor isomer, 0.26 ppm), due to shielding by the 4-carbethoxyphenyl function. In addition the olefinic proton in this isomer was shifted upfield by 0.33 ppm. A similar shift is observed for cisstilbene relative to trans-stilbene. (7) The UV absorbtion maxima also support a Z-configuration for the minor isomer; the major isomer had λmax 316 nm
(ε 2.42 x 104), whereas the minor isomer had λmax 306 nm (ε 1.17 x 104).
(6) Baker, R., et al, Angew Chem Int Ed Engl (1981) 20:117
(7) Katayama, M., et al, J Mol Spectroscopy (1960) 5:85. 2,3-Dihydro-4,4-dimethyl-1-benzopyran. Method A: To a solution of 8.6 g (0.10 mmol) of 3methyl-3-buten-l-ol in 100 mL of Et2O containing 8.3 g (0.105 mol) of pyridine, cooled in ice, was added over a period of 10 min a solution of 26.9 g (0.10 mmol) of diphenyl chlorophosphate in 100 mL of Et2O. The mixture was stirred at room temperature for 19 h, heated at reflux for 3.25 h, and then cooled. The white suspension was washed with water (2 x 50 mL), dried (Na2SO4), and concentrated to give 32.3 g of pale yellow oil. A sample (1.0 g) of the crude product was chromatographed on a 2 x 30-cm silica gel column with 10% EtOAc/hexane to give 0.70 g (71% yield) of diphenyl 3-methyl-3-buten-1-yl phosphate, a colorless oil; IR (CHCl3) 3070, 1650, 1590, 1480, 1280, 1175, 1155, 1020 (1060 sh), 950, 895 cm-1; 1H NMR (CDCl3) δ 1.72 (s, 3, CH3C=C), 2.42 (t, J = 7 Hz, 2, C=CCH2), 4.37 (q, J = 7 Hz, 2, CH2O), 4.78 (m, 2, H2C=C), 7.30 (m, 10, ArH).
To 10.5 g (40 mmol) of SnClw cooled in ice, was added 18.8 g (0.20 mol) of phenol with stirring. After 5 min, a yellow liquid was obtained. To this complex was added over a 10-min period, 14.5 g (31.9 mmol) of the crude phosphate followed by a 5-ml CS2 rinse. The resultant orange syrup was stirred at room temperature for 18 h, poured onto 300 g of ice/brine, and extracted with Et2O (2 x 300 mL). The extract was washed with 2 N NaOH (2 x 200 mL) and dilute brine (3 x 200 mL), dried (MgSO4), and concentrated to give 8.3 g of cloudy liquid, which was chromatographed on a 4.5 x 40-cm silica gel column with 2% Et2O/hexane to give 2.9 g (39% overall yield from diphenyl chloro- phosphate) of 2,3-dihydro-4,4-dimethyl-1-benzopyran as a colorless liquid; IR (CHCl3) 1610, 1575, 1480, 1445, 1290, 1245 (1230 sh), 1125, 1065, 945, 880 cm-1; 1H NMR (CDCl3) δ 1.23 (s, 6, (CH3)2C), 1.80 (t, J =
5.5 Hz, 2, CH2C(CH3)2), 4.17 (t, J = 5.5 Hz, 2, CH2O), 7.0 (m, 4, ArH); 13C M4R (CDCl3) 30.5 (C-4), 31.1 ((CH3)2C), 37.8 (C-3), 62.9 (C-2 ) , 117.0 (C-8), 120.5 (C-6), 126.9, 127.0 (C-5, C-7), 131.6 (C-4a), 153.7 ppm (C-8a).
Method B: To a degassed (3 times, argon) suspension of NaH, obtained from 2.15 g (54 mmol NaH) of 60% NaH/mineral oil, which had been washed with hexane (3 x 10 mL), in 20 mL of THF was added over a 5-min period with stirring and cooling in ice a solution of 5.0 g (53 mmol) of phenol in 55 mL of THF. The suspension was stirred for a further 10 min, treated with a solution of 7.0 g (59 mmol) of 3,3-dimethylacryloyl chloride in 27 mL of THF over a 5-min period, and then allowed to warm to room temperature over a 3h period. The suspension was poured into 150 mL of water containing 1 mL of HOAc. The mixture was stirred for 15 min and extracted with 150 mL of Et2O. The extract was washed with dilute brine (2 x 100 mL) and water (100 mL), dried (Na2SO4), and concentrated to give a pale yellow liquid. The ester was chromatographed on a 4 x 45-cm silica gel column with 10% Et2O/hexane to give 9.2 g (99% yield) of phenyl 3,3-dimethylacrylate as a pale yellow liquid; IR (CHCl3) 1730, 1650, 1495, 1130, 1070 cm-1; 1H NMR (CDCl3) δ 1.93 and 2.22 (2 s, 6, (CH3)2C), 5.92 (m, l, C=CH), 7.25 (m, 5, ArH). This purified ester (9.0 g, 51.1 mmol) in 50 mL of CH2Cl2 was added to a stirred, ice-cooled suspension of 12.0 g (90 mmol) of AlCl3 in 200 mL of CH2Cl2. This suspension was stirred at room temperature for 63 h to give a dark brown solution, which was poured onto 500 mL of ice/brine and then extracted with 150 mL of CH2Cl2. The brown extract, which contained some suspended solid and aqueous emulsion, was filtered to separate out a dark-red organic phase. The organic solution was washed with dilute brine (3 x 250 mL), dried (Na2SO4), and concentrated to give a dark-red oil, which was chromatographed on a 4 x 45-cm silica gel column with 10% Et2O/hexane to give 6.90 g (77% yield) of 2, 3-dihydro-4,4-dimethyl-2-oxo-1-benzopyran as a colorless viscous oil; IR (CHCl3) 1765, 1450,
1275, 1180, 1085, 910 cm-1; 1H IMR (CDCl3) δ 1.35 (s, 6, (CH3)2C), 2.60 (s, 3, CH2CO), 7.20 (m, 4, ArH).
To 5.0 g (132 mmol) of LiAlH4, which was stirred under argon and cooled in an ice bath, was added 75 mL of THF. This suspension was degassed (argon) and then treated with a solution of 6.0 g (34.1 mmol) of 2,3dihydro-4,4-dimethyl-2-oxo-1-benzopyran in 35 mL of THF. The suspension was refluxed for 2 h and then cooled in ice. The excess LiAlH4 was destroyed by the dropwise addition of 20% EtOAc/THF. The thick suspension was poured into 200 mL of 2 N H2SO4/ice. This mixture was saturated with NaCl and extracted with Et2O (3 x 200 mL). The extract was washed with dilute brine (3 x 100 mL), dried (Na2SO4), and concentrated to 6.2 g of white solid, the crude diol (compound 18 on page 17): IR (CHCl3) 3580, 3300, 1440, 1220, cm-1; 1H NMR (CDCl3/Me2SO-d6) δ 1.38 (s, 6, (CH3)2C), 2.13 (t, J = 7.5 Hz, 2, CH2C(CH3)2), 3.35 (t, J - 7.5 Hz, 2, CH2O), 3.4 (broad s, 1, OH, exchanged D2O), 6.9 (m, 4, ArH), 8.75 (broad s, 1, ArOH, exchanged D2O).
A solution of 5.1 g (28.3 mmol) of diol in 60 mL of pyridine was treated with 4.3 g (37.6 mmol) of methanesulfonyl chloride with stirring and cooling in an ice bath and then stirred at ice-bath temperature for 1 h. The mixture was poured into 200 mL of brine and extracted with Et2O (3 x 100 mL). The extract was washed with dilute brine (100 mL), 1 N HCl solution (2 x 200 mL), and dilute brine (2 x 100 mL), dried (MgSO4, 1 h), and concentrated to give an oil. This crude mesylate ester was dissolved in 60 ML of dioxane and treated with stirring with 75 mL of 1 N NaOH. After being stirred at room temperature for 2.25 h, the two-phase mixture was diluted with brine (100 mL) and extracted with Et2O (3 x 100 mL). The extract was washed with 75 mL of dilute brine, dried (MgSO4), and concentrated. The crude product was chromatographed on a 4.5 x 45-cm silica gel column with 3% Et2O/hexane to give 4.31 g (95% overall yield from 2,3-dihydro4, 4-dimethyl-2-oxo-1-benzopyran) of 2, 3-dihydro-4, 4dimethy1-1-benzopyran, which was spectrally identical (IR, 1H NMR) with the sample prepared by Method A.
6-Acetyl-2,3-dihydro-4,4-dimethyl-l-benzopyran. A solution of 3.6 g (45.9 mmol) of AcCl and 6.5 g (40.1 mmol) of 2, 3-dihydro-4, 4-dimethyl-1-benzopyran in 80 mL of CS2 was added dropwise over a period of 25 min to 16 g (61.3 mmol) of SnCl4 with stirring and cooling in an ice bath. The mixture was stirred at room temperature for 2.25 h to give a blue-purple suspension and then poured into 200 mL of ice/brine. The resultant purple suspension was shaken with 1 L of saturated NaHCO3 solution and 600 mL of CH2Cl2. The aqueous phase was again extracted with CH2Cl2 (400 mL), and then combined extracts were washed with NaHCO3 (500 mL), brine (2 x 500 mL), and water
(500 mL), and dried (Na2SO4). The yellow solution was concentrated to give 8.3 g of an orange-brown, viscous oil, which was chromatographed on a 4.5 x 45-cm silica gel column with 10% EtOAc/hexane to give 6.85 g of a light-green viscous liquid. A 6.0-g sample of this material was purified by bulb-to-bulb distillation at 110-115ºC (0.5 mm) to yield 5.82 g (81% yield) of 6acetyl-2, 3-dihydro-4, 4-dimethyl-1-benzopyran as a colorless viscous liquid; IR (CHCl3) 1670, 1605, 1495, 1360, 1315, 1245 (1225 sh) cm-1; 1H NMR (CDCl3) δ 1.37 (s, 6, (CH3)2C), 1.83 (t, J = 5.5 Hz, 2, CH2C(CH3)2), 2.53 (s, 3, CH3CO), 4.24 (t, J = 5.5 Hz, 2, CH2O), 6.82 (d, J = 8.5 Hz, 1, H-8), 7.72 (dd, J = 8.5, J = 2 Hz, 1, H-7), 7.98 (d, J = 2 Hz, 1, H-5); UV (MeCN) λmax 222 nm (ε 1.32 x 104), 272 nm (ε 1.48 x 104); MS calcd for C13H16O2 204.1150, found 204.1146.
(E)-1-(4-Carbethoxyphenyl)-2-(4,4-dimethyl-2,3dihydro-1-benzopyran-6-yl)-1-propene. A degassed (argon), stirred suspension of NaH, obtained from 0.52 g (13 mmol of NaH) of 60% NaH/mineral oil dispersion that was washed with hexane (3 x 3 mL), in 15 mL of THF was treated at room temperature over a 5-min period with a solution of 2.04 g (10 mmol) of 6-acetyl-2,3-dihydro-4,4-dimethyl-1-benzopyran, 3.6 g (12 mmol) of diethyl 4-carboxybenzyl phosphonate, and 0.45 g (2.0 mmol) of 15-Crown-5 in 35 mL of THF. The suspension was stirred at room temperature for 16 h to give a red gum and a red solution. The reaction mixture was treated with 200 mL of brine containing 1 mL of HOAc and extracted with Et2O (2 x 150 mL). The extract was washed with water (150 mL), dried (Na2SO4), and concentrated. The yellow oil was eluted through a 4.5 x 35-cm silica gel column with 7%
Et2O/hexane to give 3.0 g of an almost colorless gum; LC (Radialpak B, 5% Et2O/hexane, 1 mL/min, 280 nm) tR 7.3 (84.5%), 8.6 min (15.5%). Two crystallizations of this product from hexane (4 mL, then 3 mL) gave 1.98 g (57% yield) of (E)-1-(4-carbethoxyphenyl)-2-(4,4dimethyl-2,3-dihydro-1-benzopyran-6-yl)-1-propene as white needles, mp 70-71.5ºC; LC (Radialpak A, MeCN, 1 mL/min, 280 nm) tR 6.2 (98.3%), 7.0 min (1.7%); LC (Radialpak B, 5% Et2O/hexane, 1 mL/min, 280 nm) tR 7.4 (99.7%), 8.6 min (0.3%); IR (CHCl3) 1700, 1605, 1490, 1280, 1230, 1110 cm-1; 1H NMR (CDCl3) δ 1.38 (s, 6, (CH3)2C), 1.40 (t, J = 7.5 Hz, 3, CH2CH3), 1.85 (t, J = 5.5 Hz, 2, CH2C(CH3)2), 2.28 (s, 3, CH3C=CH), 4.23 (t, J = 5.5 Hz, 2, CH2O), 4.40 (q, J = 7.5 Hz, 2,
CH2CH3), 6.78 (s, 1, C=CH), 6.82 (d, J = 8.5 Hz, 1, 8Ar), 7.2-7.5 (m, 2, 5,7-Ar), 7.45 (d, J = 8.5 Hz, 2,
ArH m to CO2CH2CH3), 8.08 (d, J = 8.5 Hz, 2, ArH o to CO2CH2CH3); 13C NMR (CDCl3) 14.7, 18.0, 31.0, 31.3, 37.9, 61.1, 63.3, 117.1, 124.7, 125.1, 125.4, 128.3, 129.2, 129.7, 131.6, 136.0, 139.7, 143.6, 153.7,
166, 8 ppm (C=O ) ; UV (EtOH ) λmax 236 nm ( ε 1. 41 x 104 ) , 316 nm ( ε 2.42 x 104 ) ; M S calcd for C23H26O3 350.1882 , found 350. 1893 .
A sample of the gum obtained by concentration of the crystallization mother liquors was purified using the LC recycle technique (Et2O/hexane) to give an impure sample of (Z )-1-(4-carbethoxyphenyl)-2(4,4-dimethyl-2,3-dihydro-1-benzopyran-6-yl)-1-propene as a very pale-yellow gum; LC (Radialpak B, 5% EtO/hexane, 1 mL/min, 280 nm) tR 7.2 (7.4%), 8.4 min (92.6%); IR (CHCl3) 1705, 1605, 1495, 1370, 1280, (1230 sh), 1110, 910, 880 cm"1; 1H NMR (CDCl3) δ 1.12 (s, 6, (CH3)2C), 1.31 (t, J = 7.5 Hz, 3, CH2CH3), 1.77 (t, J = 5.5 Hz, 2, CH2C(CH3)2), 2.20 (d, J = 1.5 Hz, 3, CH3C=CH), 4.15 (t, J = 5.5 Hz, 2, CH2O), 4.32 (q, J = 7.5 Hz, 2, CH2CH3), 6.45 (s, 1, C=CH), 6.65-7.2 (m, 5, 5,7,8-ArH, ArH m to CO2CH2CH3), 7.85 (d, J = 8.5 Hz, 2, ArH o to CO2CH2CH3); UV (EtOH) λmax 244 nm (ε 1.69 x 104), 306 nm (ε 1.17 x 104); MS calcd for C23H26O3 350.1882, found 350.1887.
(E)-1-(4-Carboxyphenyl)-2-(4,4-dimethyl-2,3-dihydro-1benzopyran-6-yl)-1-propene. A degassed (argon) solution of 0.6 g (9.1 mmol) of 85% KOH in 5 mL of EtOH and 1 mL of H2O was added to 1.15 g (3.19 mmol) of (E)-1-(4-carbethoxyphenyl)-2-(4,4-dimethy1-2,3dihydro-1-benzoρyran-6-yl)-1-propene. The mixture was degassed (argon) and heated in a 110ºC oil bath for 65 min to give a clear solution. The cold white suspen- sion was diluted with 5 mL of 50% HOAc and 50 mL of brine. The product was extracted into 500 mL of 50% Et2O/THF. The extract was washed with dilute brine (2 x 100 mL), dried (MgSO4), and concentrated. The white solid was dissolved in 250 mL of 50% EtOAc/C6H6 at reflux. The hot solution was filtered through a glass wool plug, concentrated to 100 mL, and cooled to -5ºC to give 0.976 g (92% yield) of product as white crystals, mp 285-286ºC; LC (Radialpak A, MeOH, 1 mL/min, 260 nm) tR 3.3 min (100%); IR (mull) 3500, 2300, 1675, 1625, 1470, 1375, 1300, 1280, 1230, 820 cm-1; 300 MHz 1H NMR (Me2SO) δ 1.40 (s, 6, (CH3)2C), 1.84 (m, 2, CH2C), 4.20 (m, 2, CH2O), 6.88 (d, J = 8.4 Hz, 1, H-8), 7.55 (dd, J = 8.5 Hz, J = 2.1 Hz, 1, H-7), 7.80 (d, J = 2.1 Hz, 1, H-5), 7.91 (dd, J = 8 Hz, J=1.4 Hz,
1, napH-7), 7.99 (dd, J = 8 Hz, J = 0.8 Hz, 1, naρH-4 or napH-8), 8.07 (d, J = 8.7 Hz, 1, naρH-4 or napH-8),
8.16 (d, J = 8.6 Hz, 1, napH-3), 8.24 (s, 1, napH-5), 8.61 (s, 1, napH-1); 13C KMR (Me2SO-d6/CDCl3) 28.5,
28.8, 35.2, 60.7, 115.4, 122.1, 123.6, 123.9, 125.8,
126.2, 127.8, 128.4, 129.0, 129.8, 130.1, 133.6,
138.1, 151.6, 165.6 ppm; UV (95% EtOH) λ max 232 nm (ε
4.96 x 104), 268 nm (ε 3.31 x 104), 314 nm (ε 2.11 x 104); MS calcd for C22H20O3 332.1412, found
332.1410; Anal. calcd for C22H20O3: C 79.49, H 6.06; found: C 79.84, H 6.34.
Example 4. (E )-1-(4-Carbethoxyphenyl)-2-(1,4-methano¬
1,2,3,4-tetrahydro-6-naρhthyl) ethene and (E )-1-(4Carboxyphenyl)-2-(1,4-methano-1,2,3,4-tetrahydro-6- naphthyl) ethene
1,2,3,4-Tetrahydro-1,4-methano-6-naphthoic Acid. To a solution of 60 g (1.5 mol) of NaOH in 300 mL of H2O cooled to -5°C was added 25.6 mL (0.5 mol) of Br2 over a period of 5 min. The resulting solution of NaOBr was kept below 0°C, while a solution of 18.6 g (0.1 mol) of 1,2,3,4-tetrahydro-6-acetyl-1,4-methanonaphthalene in 10 mL of dioxane was added. The temperature of the reaction mixture was gradually raised to 60-65°C with a hot-water bath and was maintained there for 0.5 h. The reaction mixture was then cooled to room temperature, before a solution of 50 g (0.48 mol) of NaHSO3 in 200 mL of H2O was added. The yellow reaction mixture turned colorless. The mixture was acidified with about 120 mL of concentrated HCl; and the white, precipitated acid was extracted into 800 mL of Et2O. The ethereal solution was dried (Na2SO4) and concentrated. The crude product was recrystallized (three crops) from EtOAc to give a total of 17.67 g (94% yield) of the acid as white needles, mp 153-154°C; IR (mull) 2900-3200 (CO2H), 1680, 1280, 1110, 950, 860, 760 cm-1; 1H SMR (CDCl3) δ 1.1-2.2 (m, 6, (CH2)2, CH2), 3.45 (s, 2, 2 CH), 7.2-7.4 and 7.9-8.15 (2 m, 3, ArH), 11.65 (broad s, 1, CO2H); MS calcd for C12H12O2 188.0837, found 188.0818.
1,2,3,4-Tetrahydro-6-formyl-1,4-methanonaphthalene.
The naphthoic acid prepared as described above (9.4 g, 0.05 mol) was added slowly to a stirred suspension of 1.0 g (26.4 mmol) of LiAlH4 in 100 mL of THF. Another 0.6-g (15.8 mmol) portion of LiAlH4 was then added. This mixture was stirred at room temperature for 2 h, when TLC (25% EtOAc/hexane) indicated that no starting material remained. To the reaction mixture was slowly added 1.6 mL of H2O, 4.8 mL of 15% aqueous NaOH, and 1.6 mL of H2O. The mixture was filtered through Celite (100-mL Et2O wash). The filtrate was concentrated, and the resulting colorless oil was purified by chromatography on 150 g of silica gel (30% Et2O/hexane) to give 8.8 g (100% yield) of 1,2,3,4tetrahydro-6-hydroxymethyl-1,4-methanonaphthalene as a colorless oil: IR (film) 3200-3600 (OH), 3000, 2900, 1500, 1460, 1440, 1300, 1270, 1240, 1200, 1140, 1090, 1020, 960, 900, 880, 830, 770, 730 cm-1; 1H NMR (CDCl3) δ 0.95-2.0 (m, 6, (CH2)2, CH2), 2.93 (s, 1, OH), 3.15-3.40 (m, 2, 2 CH), 4.48 (s, 2, CH2OH), 6.97.25 (m, 3, ArH); MS calcd for C12H14O 174.1045, found 174.1058.
A solution of 50 mL (0.62 mol) of pyridine in 250 mL of CH2Cl2 was cooled in an ice-bath while 31 g (0.31 mol) of CrO3 was added in several portions over a period of 30 min. The mixture was stirred for another 15 min. Then 8.6 g (0.15 mol) of 1,2,3,4tetrahydro-6-hydroxymethyl-1,4-methanonaphthalene in 5 mL of CH2Cl2 was added. This mixture was stirred at 0°C for 20 min when TLC (25% Et20/hexane) indicated that reaction was complete. The reaction mixture was filtered through Florisil (500 mL of CH2Cl2 wash). The filtrate was concentrated and passed over 200 g of silica gel (25% Et2O/hexane) to give 6.8 g (80% yield of 1,2,3,4-tetrahydro-6-formyl-1,4-methanonaphthalene as a pale yellow oil: IR (film) 3000, 2900, 2800, 2750, 1700, 1620, 1590, 1460, 1440, 1360, 1310, 1230, 1190, 1140, 1080, 1030, 960, 840, 810, 780 cm-1; 1H NMR (CDCl3) δ 1.1-2.1 (m, 6, (CH2)2, CH2), 3.45 (broad s, 2, 2 CH), 7.3-7.8 (m, 3, ArH), 10.0 (s, 1, CHO); MS calcd for C12H12O 172.0888, found 172.0898.
(E)-1-(4-Carbethoxyphenyl)-2-(1,4-methano-1,2,3,4tetrahydronaphth-6-yl) ethene. A 1.06-g (27.4 mmol) portion of NaH-mineral oil dispersion (59.3%) was washed with three 10-mL portions of pentane, and the resulting powder was suspended in 100 mL of THF. A mixture of 4.7 g (27.3 mmol) of 1,2,3,4-tetrahydro-6formyl-1,4-methanonaphthalene, 8.19 g (27.3 mmol) of diethyl 4-carbethoxybenzyl phosphonate, and 100 mg of 15-crown-5 in 25 mL of THF was added. Hydrogen gas slowly evolved. The reaction mixture was stirred at room temperature for 2 h, and then diluted with 300 mL of H2O and extracted with Et2O (3 x 100 mL). The ethereal extracts were washed with brine (2 x 200 mL), dried (Na2SO4), and concentrated at reduced pressure to give a white solid, which was recrystallized from EtOAc to give 7.7 g (88% yield) of white crystals, mp 113-114°C; LC (Radialpak B, 2% Et2O/hexane, 2 mL/min, 260 nm) tR 12.8 min (100%); LC (Radialpak A, 10% H2O/MeCN, 2 mL/min, 260 nm), tR 7.55 min (100%); IR (mull) 1710, 1610, 1420, 1290, 1190, 1120, 1030, 970, 860, 780 cm-1; 300 MHz lH SMR (CDCl3) δ 1.20 (d, J = 8 Hz, 2, endo-2,3-H), 1.40 (t, J = 7 Hz, 3, CO2C2CH3), 1.55 (d, J = 8 Hz, 1, anti-9-H), 1.77 (d, J = 1, syn-9-H), 1.94 (d, J = 8 Hz, 2, exo-2,3-H), 3.38 (broad s, 2, 1,4-H), 4.38 (q, J = 7 Hz, 2,
CO2CH2CH3), 7.07 (d, J = 16 Hz, 1, C-2 HC=CH, 7.16 and 7.22 (2 d, J = 9 Hz, 2, 7,8-H), 7.20 (d, J = 16 Hz, 1, C-l HC=CH, 7.40 (s, 1, 5-H), 7.54 (d, J = 8 Hz, 2, 2', 6'-H), 8.01 (d, J = 8 Hz, 2, 3', 5'-H); 100 MHz 13C NMR (CDCl3) 14.3 (CH3), 27.0 and 27.1 (2, 3), 43.5 and 43.6 (1, 4), 49.0 (9), 60.8 (CH2CH3 ), 118.2, 120.7
125.1, 126.0 (2', 6'), 128.8, 129.9 (3', 5'), 131.9,
134.2, 142.1, 148.8, 148.9, 166.4 ppm (CO2); UV (EtOH) λma x 208 nm (ε 2.29 x 104), 238 nm (ε 1.27 x 104), 332 nm (ε 4.04 x 104); MS calcd for C22H22O2 318.1620, found 318.1607.
(E)-1-(4'-Carboxyphenyl)-2-(1,2,3,4-tetrahydro-1,4methanonaphth-6-yl) ethene. To a suspension of 1.5 g (4.7 mmole) of ester prepared as described above in 10 mL of EtOH was added a solution of 1.2 g
(21.4 mmole) of KOH in 5 mL of H2O and 3 mL of EtOH. The mixture was degassed three times and stirred at 80°C for 40 min under an argon atmosphere. The cooled reaction mixture was acidified with 18 mL of a 1:1 mixture of HOAc and H2O. The precipitated acid was collected by filtration and was recrystallized from EtOH to give 1.05 g (77% yield) of the acid as white plates, mp 275°C; LC (Radialpak A, 0.1% TFA in 25% H2O/MeCN, 2 mL/min, 280 nm) tR 5.38 min (0.1%), 5.83 min (99.9%); IR (mull) 2900-3200, 1690, 1620, 1440, 1340, 1300, 1190, 1120, 960, 890, 860, 830, 800, 780 cm-1; 300 MHz 1H NMR (Me2SO-d6) δ 1.10 (d, J =
8 Hz, 2, endo-2,3-H), 1.54 (d, J = 8 Hz, 1, anti-9-H), 1.67- (d, J = 1, syn-9-H), 1.91 (d, J = 8 Hz, 2, exo2,3-H), 3.32 (s, 2, 1, 4-H), 7.18 and 7.27 (2 d, J = 8 Hz, 2, 7,8-H), 7.22 and 7.35 (2 d, J = 16 Hz, 2, HC=CH), 7.50 (s, 1, 5-H), 7.67 (d, J = 8 Hz, 2,
2',6'-H), 7.92 (d, J = 8 Hz, 2, 3',5'-H), 12.84 (broad s, l, COOH); 100 MHz 13C NMR (Me2SO-d6) 26.7 (2, 3), 42.9 and 43.0 (1, 4), 48.5 (9), 118.2, 120.6, 125.2, 125.7, 126.2 (2', 6'), 129.1, 129.7 (3', 5'), 131.7, 134.1, 141.7, 148.3, 148.4, 167.1 ppm (CO2); UV (EtOH) λmax 209 nm (ε 2.31 x 104), 236 nm (ε 1.29 x 104), 326 nm (ε 3.90 x 104:; MS calcd for C20H18O2 290.1307, found 290.1312.
The retinoids of formula (1) may be used topically or systemically as chemopreventive agents and in the treatment, amelioration, or prevention of the skin, rheumatic and other disorders for which retinoic acid and other retinoids are useful. In this regard, they may be used for therapy in animals, including humans, of premalignant epithelial cell lesions, as a prophylaxis against tumor promotion in epithelial cells and treatment for dermatoses such as icthyoses, follicular disorders, benign epithelial disorders, and other proliferative skin diseases (nonmalignant conditions of the skin that are characterized by epidermal cell proliferation or incomplete cell differentiation) such as acne, psoriasis, eczema, atopic dermatitis, nonspecific dermatitis and the like. When used for such treatments they will usually be formulated with a pharmaceutical liquid, semisolid, or solid carrier. A pharmaceutically acceptable carrier is a material that is nontoxic and generally inert and does not affect the functionality of the active ingredients adversely. Such materials are well known and include those materials sometimesreferred to as diluents or vehicles in the pharmaceutical formulation art. The carrier may be organic or inorganic in nature. Examples of pharmaceutically acceptable carriers that may be used to formulate the retinoids are water, gelatin, lactose, starch, mineral oil, cocoa butter, dextrose, sucrose, sorbitol, mannitol, gum acacia, alginates, cellulose, talc, magnesium stearate, polyoxyethylene sorbitan monolaurate, and other commonly used pharmaceutical carriers. In addition to the retinoid and carrier the formulation may contain minor amounts of additives such as flavoring agents, coloring agents, thickening or gelling agents, emulsifiers, wetting agents, buffers, stabilizers, and preservatives such as antioxidants.
For topical administration the retinoids are conveniently provided in the form of ointments, tinctures, creams, solutions, lotions, sprays, suspensions, and the like. The amount of retinoid in such topical formulations will normally be in the range of about 0.01 to about 1% by weight. For enteral (oral or rectal) administration the retinoids will typically be formulated as tablets, capsules, dragees, syrups, solutions, or suppositories. For parenteral administration the retinoids will be formulated as injectable solutions or suspensions.
The dosages and dosage regimen in which the retinoids are administered will vary according to the dosage form, mode of administration, the condition being treated and particulars of the patient being treated. They will, of course, be administered in chemopreventive (tumor promotion inhibiting) amounts or therapeutically effective amounts. For adult humans such chemopreventive amounts will usually be about 0.01 mg to 10.0 mg daily given in one or more doses. Oral doses will generally be more than topical doses and doses for treating skin disorders will typically be less than doses administered for cancer chemoprevention. The dose for treating skin disorders will be on the order of, but normally less than, the dose of retinoic acid prescribed for the disorder. The usefulness of the invention compounds was demonstrated by testing the compounds of the
Examples in the ornithine decarboxylase (ODC) assay, Verma, A.K. and Boutwell, R.K., Cancer Res (1977) 37:2196-2201, and the tracheal organ culture assay, Newton, D.L.; Henderson, W.R.; and Sporn, M.B., Cancer Res (1980) 40:3413-3425. The ODC assay measures a compound's ability to prevent the induction of ODC. The tracheal organ culture assay measures a compound's ability to reverse keratinization.
The ODC assay is carried out as follows. Female Charles River CD-I mice from Charles River
Breeding Laboratories, Wilmington, Massachusetts, are used (age 7 to 9 weeks). The dorsal hair of the mice is shaved 1 to 2 days before testing, and only mice showing no hair regrowth are used. A single dose of 12-O-tetradecanoylphorbol-13-acetate (TPA) (10.5 μg, 17 nmol) in 0.2 mL of acetone is applied topically to the back of each mouse. The test compound, at one of three dose levels (1.7, 17 and 170 nmol), dissolved in 0.2 mL of acetone is applied 1 hour before the TPA treatment to the test groups; the control group is treated with acetone alone. The mice are killed by cervical dislocation five hours after TPA treatment. Determinations are done in triplicate. The epidermis is obtained from the sacrificed animals. To obtain sufficient material, the dorsal skins from 2 to 3 mice in each treatment group are pooled. The depilatory agent Nudit® (Helena Rubinstein, New York) is applied to the shaved area of the skin; after 5 minutes, it is washed off thoroughly with cold tap water. Then the skin is excised and plunged immediately into ice-cold water; it is then placed in a 55°C water bath for 30 seconds and reimmersed in ice-cold water for at least another 30 seconds. The skin is placed epidermis side up on a cold plate, and the epidermis is scraped off with a razor blade. The pooled epidermal sheets are homogenized (Polytron PT-10 homogenizer) at 0° to 4°C for 1520 seconds in 50 mM sodium phosphate and 0.1 mM ethylenediaminetetraacetic acid (EDTA), at a volume of 1 mL/skin.
The supernatant fraction remaining after centrifugation of the homogenate at 10,000 x g for 30 seconds at 0°C is used for the enzyme assay. Enzyme activity is determined using the microassay for ODC as described by Verma and Boutwell to measure the release of 14CO2 from DL-[1-14C]-ornithine (58 mCi/mmol) after incubation with the 10,000 x g supernatant. The incubations are carried out by decanting, with a Pasteur pipette, 100 μL of the supernatant containing 100 to 120 μg of protein into two or three 15-mL Corex tubes in a shaking water bath at 37°C. The assay mixture in the tubes consists of 50 μL of 100 πM sodium phosphate buffer (pH 7.2), 10 μL of 4 πM pyridoxal phosphate, 40 μL of 25 mM dithiothreitol, and 1 μL of 0.1 M EDTA. The center wells in the tubes are filled with 200 μL of a 2:1 solution (v/v) of ethanolamine:2methoxyethanol. The reaction is started by adding 50 μL of substrate (0.5 μCi of DL-[1-14C]-ornithine in 2 mM cold ornithine) at 1-minute intervals by injection to each of the stoppered tubes. Incubations are routinely carried out at 37ºC for 30 to 60 minutes. The reaction is stopped by addition of 0.5 ml of 2 M citric acid, and incubation is continued for an additional hour without heating to ensure complete absorption of 14CO2.
Radioactivity is measured using a toluenebased scintillant (4 g of PPO and 50 mg of POPOP/L of toluene) in a Beckman LS-250 liquid scintillation counter. Enzyme activity is determined in triplicate and expressed as nanomoles of CO2 released in 30 minutes per milligram of protein. Enzyme activity is linear for the protein concentration used. The protein concentrations of the epidermal extracts are determined by the Lowry procedure, using bovine serum albumin as the standard.
The tracheal organ culture assay is carried out as follows. Tracheas are taken from hamsters that are in very early stages of vitamin A deficiency and placed in organ culture. At the time of culture, the animals are still gaining weight; the tracheal epithelium is generally low columnar or cuboidal, with only occasional patches of squamous metaplasia. Each trachea is opened from the larynx to the carina along the membranous dorsal wall and cultured in a serumfree medium (CMRL-1066; with crystalline bovine insulin, 0.1 μg/ml; hydrocortisone hemisuccinate, 0.1 μg/ml; glutamine, 2 mM; penicillin, 100 units/ml; and streptomycin, 100 μg/ml, added). Cultures are gassed with 50% oxygen, 45% nitrogen, and 5% CO2. The culture dishes are rocked at 35.5-36.0 degrees to allow the tracheas contact with both gas and medium. All tracheas are grown in medium containing no retinoid for the first 3 days. At the end of 3 days, some tracheas are harvested; almost all of these tracheas have significant squamous metaplasia, and approximately 60% have keratinized lesions. The remaining tracheas are then divided into different groups which are treated with either: 1) retinoid dissolved in dimethylsulfoxide (final concentration of DMSO in culture medium is never greater than 0.1%) or 2) an equivalent amount of DMSO alone. Culture medium is changed three times a week, and all of the remaining tracheas are harvested at the end of 10 days in culture. Tracheas are fixed in 10% buffered formalin and embedded in paraffin. Cross sections of five micrometers are made through the mid-portion, stained with hematoxylin and eosin, and then scored with a microscope for the presence of keratin and keratohyaline granules, both of which are found in approximately 90% of control cultures that received no retinoid for the entire 10 day culture period. Retinoids are scored as "inactive" if both keratin and keratohyaline granules are seen; they are scored as "active" if neither keratin nor keratohyaline granules are seen, or if keratohyaline granules alone are absent. The table below gives the results of these tests.
Figure imgf000053_0001

Claims

Claims
1. A compound of the formula:
Figure imgf000054_0002
where A is the substituent system of a fused ring selected from:
and R1 , R2, R3 and R4 are hydrogen or methyl, X is hydrogen or fluorine and Q is:
Figure imgf000055_0001
where X is hydrogen, hydroxy, methoxy or fluorine, R is hydroxy, alkoxy with 0 or 1 hydroxy substituent, aroxy or NR5R6, where R5 is hydrogen, alkyl with 0 or
1 hydroxy substituent or aryl, and R6 is alkyl with 0 or 1 hydroxy substituent or aryl, with the provisos that X is fluorine only when R2 is methyl, when R3 or R4 is methyl the other R3 or R4 is also methyl, and when Q is (i) Q may be in either the cis or trans position.
2. The compound of claim 1 wherein the alkoxy group represented by R contains 1 to about 10 carbon atoms with 0 or 1 hydroxy substituent, the aroxy group represented by R contains 6 to about 15 carbon atoms, the alkyl groups represented by R5 and R6 each contain 1 to about 8 carbon atoms with 0 or 1 hydroxy substituent and the aryl groups represented by R5 and R6 each contain 6 to about 15 carbon atoms with 0 or 1 hydroxy substituents.
3. The compound of claim 1 wherein the alkoxy group represented by R contains 1 to 4 carbon atoms with 0 or 1 hydroxy substituent, the aroxy group represented by R is phenoxy, monohydroxyphenoxy, or monoalkoxyphenoxy, where the alkoxy group contains 1 to 4 carbon atoms, the alkyl groups represented by R5 and R6 each contain 1 to 4 carbon atoms and have 0 or 1 hydroxy substituent and the aryl groups represented by R5 and R6 are phenyl, 4-hydroxyphenyl, or 4methoxyphenyl.
4. The compound of claim 1 where R is ethoxy or hydroxy.
5. A compound of the formula:
Figure imgf000056_0001
where R is ethoxy or hydroxy .
6. A compound of the formula:
Figure imgf000057_0003
where R is ethoxy or hydroxy.
7. A compound of the formula:
Figure imgf000057_0002
where R is ethoxy or hydroxy.
8. A compound of the formula:
Figure imgf000057_0001
where R is ethoxy or hydroxy.
9. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 1 combined with a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 2 combined with a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 3 combined with a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 4 combined with a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 5 combined with a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 6 combined with a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 7 combined with a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 8 combined with a pharmaceutically acceptable carrier.
17. A chemopreventive composition for inhibiting tumor promotion in epithelial cells in a living animal comprising a tumor promotion inhibiting amount of the compound of claim 1 combined with a pharmaceutically acceptable carrier.
18. A chemopreventive composition for inhibiting tumor promotion in epithelial cells in a living animal comprising a tumor promotion inhibiting amount of the compound of claim 2 combined with a pharmaceutically acceptable carrier.
19. A chemopreventive composition for inhibiting tumor promotion in epithelial cells in a living animal comprising a tumor promotion inhibiting amount of the compound of claim 3 combined with a pharmaceutically acceptable carrier.
20. A chemopreventive composition for inhibiting tumor promotion in epithelial cells in a living animal comprising a tumor promotion inhibiting amount of the compound of claim 4 combined with a pharmaceutically acceptable carrier.
21. A chemopreventive composition for inhibiting tumor promotion in epithelial cells in a living animal comprising a tumor promotion inhibiting amount of the compound of claim 5 combined with a pharmaceutically acceptable carrier.
22. A chemopreventive composition for inhibiting tumor promotion in epithelial cells in a living animal comprising a tumor promotion inhibiting amount of the compound of claim 6 combined with a pharmaceutically acceptable carrier.
23. A chemopreventive composition for inhibiting tumor promotion in epithelial cells in a living animal comprising a tumor promotion inhibiting amount of the compound of claim 7 combined with a pharmaceutically acceptable carrier.
24. A chemopreventive composition for inhibiting tumor promotion in epithelial cells in a living animal comprising a tumor promotion inhibiting amount of the compound of claim 8 combined with a pharmaceutically acceptable carrier.
25. A therapeutic composition for treating a nonmalignant skin disorder comprising a therapeutically effective amount of the compound of claim 1 combined with a pharmaceutically acceptable carrier.
26. A therapeutic composition for treating a nonmalignant skin disorder comprising a therapeutically effective amount of the compound of claim 2 combined with a pharmaceutically acceptable carrier.
27. A therapeutic composition for treating a nonmalignant skin disorder comprising a therapeutically effective amount of the compound of claim 3 combined with a pharmaceutically acceptable carrier.
28. A therapeutic composition for treating a nonmalignant skin disorder comprising a therapeutically effective amount of the compound of claim 4 combined with a pharmaceutically acceptable carrier.
29. A therapeutic composition for treating a nonmalignant skin disorder comprising a therapeutically effective amount of the compound of claim 5 combined with a pharmaceutically acceptable carrier.
30. A therapeutic composition for treating a nonmalignant skin disorder comprising a therapeutically effective amount of the compound of claim 6 combined with a pharmaceutically acceptable carrier.
31. A therapeutic composition for treating a nonmalignant skin disorder comprising a therapeutically effective amount of the compound of claim 7 combined with a pharmaceutically acceptable carrier.
32. A therapeutic composition for treating a nonmalignant skin disorder comprising a therapeutically effective amount of the compound of claim 8 combined with a pharmaceutically acceptable carrier.
33. A method of inhibiting tumor promotion in epithelial cells of a human or other living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 1 to the animal.
34. A method of inhibiting tumor promotion in epithelial cells of a human or other living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 2 to the animal.
35. A method of inhibiting tumor promotion in epithelial cells of a human or other living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 3 to the animal.
36. A method of inhibiting tumor promotion in epithelial cells of a human or other living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 4 to the animal.
37. A method of inhibiting tumor promotion in epithelial cells of a human or other living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 5 to the animal.
38. A method of inhibiting tumor promotion in epithelial cells of a human or other living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 6 to the animal.
39. A method of inhibiting tumor promotion in epithelial cells of a human or other living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 7 to the animal.
40. A method of inhibiting tumor promotion in epithelial cells of a human or other living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 8 to the animal.
41. A method of treating a human or other living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 1 to the animal.
42. A method for treating a human or other living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 2 to the animal.
43. A method for treating a human or other living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 3 to the animal.
44. A method for treating a human or other living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 4 to the animal.
45. A method for treating a human or other living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 5 to the animal.
46. A method for treating a human or other living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 6 to the animal.
47. A method for treating a human or other living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 7 to the animal.
48. A method for treating a human or other living animal for a nonmalignant skin disorder comprising administering a thrapeutically effective amount of the compound of claim 8 to the animal.
PCT/US1984/000280 1983-08-08 1984-02-24 Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues WO1985000806A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52139583A 1983-08-08 1983-08-08
US521,395 1983-08-08

Publications (1)

Publication Number Publication Date
WO1985000806A1 true WO1985000806A1 (en) 1985-02-28

Family

ID=24076576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1984/000280 WO1985000806A1 (en) 1983-08-08 1984-02-24 Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues

Country Status (2)

Country Link
EP (1) EP0155940A1 (en)
WO (1) WO1985000806A1 (en)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2569689A1 (en) * 1984-09-05 1986-03-07 Oreal NOVEL BENZONORBORNENE DERIVATIVES, PROCESSES FOR PREPARING THEM AND MEDICAMENTARY AND COSMETIC COMPOSITIONS CONTAINING SAME
FR2596759A1 (en) * 1986-04-04 1987-10-09 Oreal NOVEL CHROMANE AND THIOCHROMAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND DRUG AND COSMETIC COMPOSITIONS CONTAINING SAME
EP0350846A2 (en) * 1988-07-14 1990-01-17 F. Hoffmann-La Roche Ag Condensed heterocyclic compounds and their use in therapy
US5164387A (en) * 1988-07-14 1992-11-17 Hoffmann-Laroche Inc. Condensed heterocyclic compounds
EP0568898A1 (en) * 1992-05-07 1993-11-10 F. Hoffmann-La Roche Ag Benzothiepine-, benzothiopyrane- and benzothiophenyle derivatives, their preparation and use as medicine
US5324840A (en) * 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
EP0637297A1 (en) * 1992-04-22 1995-02-08 Ligand Pharmaceuticals, Inc. Compounds having selectivity for retinoid x receptors
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5498755A (en) * 1994-08-23 1996-03-12 Chandraratna; Roshantha A. Disubstituted aryl and heteroaryl imines having retinoid-like biological activity
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5516904A (en) * 1989-12-29 1996-05-14 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity
US5534516A (en) * 1989-09-19 1996-07-09 Allergan Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1, 2, 3, 4-tetrahydroquinolinyl group having retinoid-like activity
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5556996A (en) * 1994-12-29 1996-09-17 Allergan Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity
EP0736530A2 (en) * 1995-04-05 1996-10-09 Bristol-Myers Squibb Company Retinoid-like heterocycles
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5602135A (en) * 1993-10-18 1997-02-11 Allergan Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US5602130A (en) * 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5616712A (en) * 1995-05-16 1997-04-01 Allergan Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5618931A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5618943A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5618836A (en) * 1993-12-30 1997-04-08 Allergan [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US5663347A (en) * 1987-03-20 1997-09-02 Allergan Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5663367A (en) * 1995-06-06 1997-09-02 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5672710A (en) * 1995-11-03 1997-09-30 Allergan Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US5675024A (en) * 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5677323A (en) * 1989-09-19 1997-10-14 Allergan Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1, 2, 3, 4, -tetrahydroquinolinyl group having retinoid-like activity
US5688957A (en) * 1995-12-29 1997-11-18 Allergan (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity
US5698700A (en) * 1994-12-29 1997-12-16 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
WO1998007716A2 (en) * 1996-08-23 1998-02-26 The Board Of Regents For Oklahoma State University Heteroarotinoids-anticancer agents with receptor specificity and tgase activity
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5741896A (en) * 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5747542A (en) * 1996-06-21 1998-05-05 Allergan Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US6172115B1 (en) 1993-02-11 2001-01-09 Allergan Sales, Inc. Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid
US6252090B1 (en) 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6369225B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6534544B1 (en) 1995-12-29 2003-03-18 Allergan Sales, Inc. Methods of treatment with compounds having RARα receptor specific or selective activity
US6586460B1 (en) 2001-04-02 2003-07-01 The Board Of Regents For Oklahoma State University Heteroarotinoids containing urea or thiourea linker
US6603019B2 (en) 2000-08-29 2003-08-05 Allergan, Inc. 1-imidazolyl substituted tetrahydronaphthalene derivatives as inhibitors of eytochrome P450RAI
US6740676B2 (en) 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002742A1 (en) * 1977-12-22 1979-07-11 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Stilbene derivatives, their preparation and medicines containing these stilbene derivatives
EP0084667A2 (en) * 1982-01-23 1983-08-03 BASF Aktiengesellschaft Phenylethylene derivatives, their preparation and use as medicines
GB2119801A (en) * 1982-05-12 1983-11-23 Hoffmann La Roche Heterocyclic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002742A1 (en) * 1977-12-22 1979-07-11 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Stilbene derivatives, their preparation and medicines containing these stilbene derivatives
EP0084667A2 (en) * 1982-01-23 1983-08-03 BASF Aktiengesellschaft Phenylethylene derivatives, their preparation and use as medicines
GB2119801A (en) * 1982-05-12 1983-11-23 Hoffmann La Roche Heterocyclic compounds

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2569689A1 (en) * 1984-09-05 1986-03-07 Oreal NOVEL BENZONORBORNENE DERIVATIVES, PROCESSES FOR PREPARING THEM AND MEDICAMENTARY AND COSMETIC COMPOSITIONS CONTAINING SAME
US5053547A (en) * 1984-09-05 1991-10-01 L'oreal Benzonorbornene derivatives, processes for their preparation and medicinal and cosmetic compositions containing them
FR2596759A1 (en) * 1986-04-04 1987-10-09 Oreal NOVEL CHROMANE AND THIOCHROMAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND DRUG AND COSMETIC COMPOSITIONS CONTAINING SAME
US5663347A (en) * 1987-03-20 1997-09-02 Allergan Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5677451A (en) * 1987-03-20 1997-10-14 Allergan Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5602130A (en) * 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5037825A (en) * 1988-07-14 1991-08-06 Hoffmann-La Roche Inc. Condensed heterocyclic compounds
US5300522A (en) * 1988-07-14 1994-04-05 Hoffmann-La Roche Inc. Condensed heterocyclic compounds and pharmaceutical use thereof
US5164387A (en) * 1988-07-14 1992-11-17 Hoffmann-Laroche Inc. Condensed heterocyclic compounds
US5420273A (en) * 1988-07-14 1995-05-30 Hoffman-La Roche Inc. Condensed heterocyclic compounds
EP0350846A3 (en) * 1988-07-14 1990-11-07 F. Hoffmann-La Roche Ag Condensed heterocyclic compounds and their use in therapy
EP0350846A2 (en) * 1988-07-14 1990-01-17 F. Hoffmann-La Roche Ag Condensed heterocyclic compounds and their use in therapy
US5599819A (en) * 1989-09-19 1997-02-04 Allergan Acetylenes disubstituted with a thienyl or furyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4 - tetrahydroquinolinyl group having retinoid-like activity
US5677323A (en) * 1989-09-19 1997-10-14 Allergan Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1, 2, 3, 4, -tetrahydroquinolinyl group having retinoid-like activity
US5534516A (en) * 1989-09-19 1996-07-09 Allergan Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1, 2, 3, 4-tetrahydroquinolinyl group having retinoid-like activity
US5616597A (en) * 1989-09-19 1997-04-01 Allergan Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4--tetrahydroquinolinyl group having retinoid-like activity
US5516904A (en) * 1989-12-29 1996-05-14 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity
EP0637297A4 (en) * 1992-04-22 1995-09-20 Ligand Pharm Inc Compounds having selectivity for retinoid x receptors.
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
EP0983991A3 (en) * 1992-04-22 2001-01-17 Ligand Pharmaceuticals, Inc. Compounds having selectivity for retinoid x receptors
EP0637297A1 (en) * 1992-04-22 1995-02-08 Ligand Pharmaceuticals, Inc. Compounds having selectivity for retinoid x receptors
US6043279A (en) * 1992-04-22 2000-03-28 Ligand Pharmaceuticals, Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
EP0983991A2 (en) * 1992-04-22 2000-03-08 Ligand Pharmaceuticals, Inc. Compounds having selectivity for retinoid x receptors
US5512683A (en) * 1992-05-07 1996-04-30 Hoffmann-La Roche Inc. Alkyl or alkoxy substituted S-heterocyclic retinoids
AU666715B2 (en) * 1992-05-07 1996-02-22 F. Hoffmann-La Roche Ag Heterocyclic compounds
EP0568898A1 (en) * 1992-05-07 1993-11-10 F. Hoffmann-La Roche Ag Benzothiepine-, benzothiopyrane- and benzothiophenyle derivatives, their preparation and use as medicine
US5324840A (en) * 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US6624188B1 (en) 1992-06-11 2003-09-23 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US6172115B1 (en) 1993-02-11 2001-01-09 Allergan Sales, Inc. Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid
US6627652B1 (en) 1993-02-11 2003-09-30 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5602135A (en) * 1993-10-18 1997-02-11 Allergan Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US5696162A (en) * 1993-10-18 1997-12-09 Allergan Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compound having retinoid like biological activity
US5618836A (en) * 1993-12-30 1997-04-08 Allergan [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
US5498755A (en) * 1994-08-23 1996-03-12 Chandraratna; Roshantha A. Disubstituted aryl and heteroaryl imines having retinoid-like biological activity
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5556996A (en) * 1994-12-29 1996-09-17 Allergan Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity
US5648503A (en) * 1994-12-29 1997-07-15 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5591858A (en) * 1994-12-29 1997-01-07 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5605915A (en) * 1994-12-29 1997-02-25 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5618943A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5618931A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5723620A (en) * 1994-12-29 1998-03-03 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5654469A (en) * 1994-12-29 1997-08-05 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5698700A (en) * 1994-12-29 1997-12-16 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
AU695432B2 (en) * 1995-04-05 1998-08-13 Bristol-Myers Squibb Company Retinoid-like heterocycles
EP0736530A2 (en) * 1995-04-05 1996-10-09 Bristol-Myers Squibb Company Retinoid-like heterocycles
EP0736530A3 (en) * 1995-04-05 1997-02-05 Bristol Myers Squibb Co Retinoid-like heterocycles
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US6369100B1 (en) 1995-04-26 2002-04-09 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5616712A (en) * 1995-05-16 1997-04-01 Allergan Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5663367A (en) * 1995-06-06 1997-09-02 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5780647A (en) * 1995-06-06 1998-07-14 Allergan 2,4-Pentadienoic acid derivatives having retinoid-like biological activity
US5672710A (en) * 1995-11-03 1997-09-30 Allergan Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US5675024A (en) * 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5688957A (en) * 1995-12-29 1997-11-18 Allergan (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity
US6534544B1 (en) 1995-12-29 2003-03-18 Allergan Sales, Inc. Methods of treatment with compounds having RARα receptor specific or selective activity
US6610744B2 (en) 1995-12-29 2003-08-26 Allergan, Inc. Methods of treatment with compounds having RARα receptor specific or selective activity
US5747542A (en) * 1996-06-21 1998-05-05 Allergan Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5741896A (en) * 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
WO1998007716A2 (en) * 1996-08-23 1998-02-26 The Board Of Regents For Oklahoma State University Heteroarotinoids-anticancer agents with receptor specificity and tgase activity
WO1998007716A3 (en) * 1996-08-23 1998-03-26 Univ Oklahoma State Heteroarotinoids-anticancer agents with receptor specificity and Tgase activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US6603019B2 (en) 2000-08-29 2003-08-05 Allergan, Inc. 1-imidazolyl substituted tetrahydronaphthalene derivatives as inhibitors of eytochrome P450RAI
US6252090B1 (en) 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6495552B2 (en) 2000-08-29 2002-12-17 Allergan, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6531599B2 (en) 2000-08-29 2003-03-11 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6855512B2 (en) 2000-08-29 2005-02-15 Allergan, Inc. Methods for identifying inhibitors of cytochrome P450RAI
US6359135B1 (en) 2000-08-29 2002-03-19 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6399774B1 (en) 2000-08-29 2002-06-04 Allergen Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6387892B1 (en) 2000-08-29 2002-05-14 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6369225B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6713647B2 (en) 2000-08-29 2004-03-30 Allergan, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6586460B1 (en) 2001-04-02 2003-07-01 The Board Of Regents For Oklahoma State University Heteroarotinoids containing urea or thiourea linker
US6740676B2 (en) 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US7351737B2 (en) 2002-03-19 2008-04-01 Allergan, Inc. 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity

Also Published As

Publication number Publication date
EP0155940A1 (en) 1985-10-02

Similar Documents

Publication Publication Date Title
WO1985000806A1 (en) Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues
US4826984A (en) Heteroarotinoid compounds as anticancer agents
US4925979A (en) Flavone carboxylic acid derivatives
EP1117628B1 (en) 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
US4454341A (en) Naphthyl or tetrahydronaphthyl-substituted naphthoic acid and derivatives
Dawson et al. Conformationally restricted retinoids
JPH08506816A (en) Pharmaceutical use of compounds having selective agonist-like activity for RXR retinoid receptor
Asato et al. Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity
AU576884B2 (en) Transdermal delivery of azatadine
US5318993A (en) Antihyperlipidemic benzoquinones
Dawson et al. Retinoic acid analogs with ring modifications. Synthesis and pharmacological activity
Spruce et al. Novel heteroarotinoids: synthesis and biological activity
US4456618A (en) Naphthenic and heterocyclic retinoic acid analogues
US6403638B1 (en) 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
Torrance et al. New monoterpenes from Artemisia filifolla. Structure, synthesis, rearrangements and biosynthesis
US4977276A (en) Heteroarotinoids as anticancer agents
US4833254A (en) Heteroarotinoids as anticancer agents
US3931232A (en) 3-Alkyl xanthene compounds
Spruce et al. Heteroarotinoids. Synthesis, characterization, and biological activity in terms of an assessment of these systems to inhibit the induction of ornithine decarboxylase activity and to induce terminal differentiation of HL-60 cells
US4439614A (en) 5,6-Methano-5,6-dihydroretinoids
US5204373A (en) Farnesylated tetrahydro-naphthalenols as hypolipidemic agents
US4532343A (en) Aromatic retinoic acid analogues
US4490414A (en) Open chain analogues of retinoic acid
EP0123679A1 (en) Esters of retinoic acid and pentaerythritol and monobenzal acetals thereof
House et al. Perhydroindan derivatives. 19. Opening of a cyclopropyl ketone that is part of an indanone system

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): DE DK FI GB JP NO SE

AL Designated countries for regional patents

Designated state(s): CH FR NL

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642